
<html lang="en"     class="pb-page"  data-request-id="963c2a35-fd62-4d59-9910-7bc153931811"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00176;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-10;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)" /></meta><meta name="dc.Creator" content="Xuesong  Liu" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Junjie  Wang" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Juan  Ge" /></meta><meta name="dc.Creator" content="Qingwang  Liu" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Zhenquan  Hu" /></meta><meta name="dc.Creator" content="Zongru  Jiang" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Mingfeng  Bai" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Description" content="Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as the first-line treatment of GISTs, doz..." /></meta><meta name="Description" content="Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as the first-line treatment of GISTs, doz..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 2, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00176" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00176" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00176" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00176" /></link>
        
    
    

<title>Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00176" /></meta><meta property="og:title" content="Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0019.jpeg" /></meta><meta property="og:description" content="Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as the first-line treatment of GISTs, dozens of drug-acquired resistant mutations emerge, and c-KIT T670I is one of the most common mutants among them. Although several kinase inhibitors are capable of overcoming the T670I mutant, none of them can achieve the selectivity over the c-KIT wild-type (wt), which also plays important roles in a variety of physiological functions such as hematopoiesis. Starting from axitinib, through fragment hybrid type II kinase inhibitor design approach, we have discovered a novel inhibitor 24, which not only exhibits potent activity to c-KIT T670I mutant but also achieves 12-fold selectivity over c-KIT wt. Compound 24 displays good antiproliferative effects against c-KIT T670I mutant-driven GIST cell lines (GIST-T1/T670I and GIST-5R) and also exhibits suitable in vivo pharmacokinetic profiles as well as dose-dependent antitumor efficacy. This study provides a proof of concept for developing a c-KIT mutant selective inhibitor that theoretically can render a better therapeutic window." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00176"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00176">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00176&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00176&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00176&amp;href=/doi/10.1021/acs.jmedchem.9b00176" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5006-5024</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00132" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00041" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (<i>E</i>)-<i>N</i><sup>1</sup>-(3-Fluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xuesong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuesong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuesong++Liu">Xuesong Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beilei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beilei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ziping Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ziping Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fengming Zou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengming Zou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junjie Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junjie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junjie++Wang">Junjie Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aoli Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aoli Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juan Ge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juan Ge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Ge">Juan Ge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingwang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingwang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingwang++Liu">Qingwang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kailin Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kailin Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenquan Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenquan Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenquan++Hu">Zhenquan Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zongru Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zongru Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zongru++Jiang">Zongru Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenchao Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenchao Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tao Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precedo Pharmaceuticals Inc., Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingfeng Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingfeng Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingfeng++Bai">Mingfeng Bai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingsong Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingsong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Institutes of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e49597888d91ddd3a48c898288ca8587ca878a"><span class="__cf_email__" data-cfemail="bccdcfd0d5c9858bfcd4d1dad092dddf92dfd2">[email protected]</span></a>. Phone: 86-551-65595161 (Q.L.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jing Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d4bebdbab3b8bda194bcb9b2b8fab5b7fab7ba"><span class="__cf_email__" data-cfemail="6d0704030a0104182d05000b01430c0e430e03">[email protected]</span></a>. Phone: 86-551-65593186 (J.L.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00176&amp;href=/doi/10.1021%2Facs.jmedchem.9b00176" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5006–5024</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 2, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 January 2019</li><li><span class="item_label"><b>Published</b> online</span>2 May 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00176" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00176</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5006%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXuesong%2BLiu%252C%2BBeilei%2BWang%252C%2BCheng%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D10%26contentID%3Dacs.jmedchem.9b00176%26title%3DDiscovery%2Bof%2B%2528E%2529-N1-%25283-Fluorophenyl%2529-N3-%25283-%25282-%2528pyridin-2-yl%2529vinyl%2529-1H-indazol-6-yl%2529malonamide%2B%2528CHMFL-KIT-033%2529%2Bas%2Ba%2BNovel%2Bc-KIT%2BT670I%2BMutant%2BSelective%2BKinase%2BInhibitor%2Bfor%2BGastrointestinal%2BStromal%2BTumors%2B%2528GISTs%2529%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5024%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00176"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1876</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00176" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xuesong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Junjie&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Ge&quot;},{&quot;first_name&quot;:&quot;Qingwang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Zhenquan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Zongru&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Mingfeng&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;5006-5024&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00176&quot;},&quot;abstract&quot;:&quot;Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as the first-line treatment of GISTs, dozens of drug-acquired resistant mutations emerge, and c-KIT T670I is one of the most common mutants among them. Although several kinase inhibitors are capable of overcoming the T670I mutant, none of them can achieve the selectivity over the c-KIT wild-type (wt), which also plays important roles in a variety of physiological functions such as hematopoiesis. Starting from axitinib, through fragment hybrid type II kinase inhibitor design approach, we have discovered a novel inhibitor 24, which not only exhibits potent activity to c-KIT T670I mutant but also achieves 12-fold selectivity over c-KIT wt. Compound 24 displays good antiproliferative effects against c-KIT T670I mutant-driven GIST cell lines (GIST-T1/T670I and GIST-5R) and also exhibits suitable in vivo pharmacokinetic profiles as well as dose-dependent antitum&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00176&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00176" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00176&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00176" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00176&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00176" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00176&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00176&amp;href=/doi/10.1021/acs.jmedchem.9b00176" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00176" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00176" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00176%26sid%3Dliteratum%253Aachs%26pmid%3D31046271%26genre%3Darticle%26aulast%3DLiu%26date%3D2019%26atitle%3DDiscovery%2Bof%2B%2528E%2529-N1-%25283-Fluorophenyl%2529-N3-%25283-%25282-%2528pyridin-2-yl%2529vinyl%2529-1H-indazol-6-yl%2529malonamide%2B%2528CHMFL-KIT-033%2529%2Bas%2Ba%2BNovel%2Bc-KIT%2BT670I%2BMutant%2BSelective%2BKinase%2BInhibitor%2Bfor%2BGastrointestinal%2BStromal%2BTumors%2B%2528GISTs%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D10%26spage%3D5006%26epage%3D5024%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292580" title="Binding modes">Binding modes</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/jmcmar.2019.62.issue-10/20190523/jmcmar.2019.62.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as the first-line treatment of GISTs, dozens of drug-acquired resistant mutations emerge, and c-KIT T670I is one of the most common mutants among them. Although several kinase inhibitors are capable of overcoming the T670I mutant, none of them can achieve the selectivity over the c-KIT wild-type (wt), which also plays important roles in a variety of physiological functions such as hematopoiesis. Starting from axitinib, through fragment hybrid type II kinase inhibitor design approach, we have discovered a novel inhibitor <b>24</b>, which not only exhibits potent activity to c-KIT T670I mutant but also achieves 12-fold selectivity over c-KIT wt. Compound <b>24</b> displays good antiproliferative effects against c-KIT T670I mutant-driven GIST cell lines (GIST-T1/T670I and GIST-5R) and also exhibits suitable in vivo pharmacokinetic profiles as well as dose-dependent antitumor efficacy. This study provides a proof of concept for developing a c-KIT mutant selective inhibitor that theoretically can render a better therapeutic window.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm in the gastrointestinal tract. The overall incidence of GISTs ranges between 6.5 and 14.5 per million each year in Europe and America.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Approximately 95% of GISTs express c-KIT, and the majority of them harbor activating mutations of c-KIT, which play a critical pathogenic role in the development of GISTs.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> c-KIT kinase belongs to type III receptor tyrosine kinase family, which also includes FLT3, platelet-derived growth factor receptors (PDGFRs), and colony stimulating factor 1 receptor (CSF1R). Upon activation, c-KIT is involved in cell survival, migration, and proliferation depending on the cell type.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Early hematopoietic cells,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> maturation cells, such as mast cells and dendritic cells,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and fully differentiated cells<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> are also dependent on c-KIT for proliferation, survival, and normal functions. In addition, c-KIT actively triggers cell death in a variety of cancer cell lines except when engaged by its ligand stem cell factor. c-KIT acts both as a proto-oncogene via its kinase activity and as a tumor suppressor via its dependence receptor activity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Gain-of-function mutations of c-KIT drive the pathology of several diseases especially the GITSs; therefore, there have been extensive drug discovery efforts targeting this kinase.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Imatinib (<b>1</b>) was approved as the first-line therapy for advanced GISTs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, about 14% of the patients were insensitive to compound <b>1</b> initially<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and more than a half of responding patients developed drug resistance due to the acquisition of secondary mutations in kinase domain such as T670I within 2 years of treatment.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> Sunitinib (<b>2</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and regorafenib (<b>3</b>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> were approved as the second and third line therapy, respectively, for GISTs to overcome some imatinib-resistant mutants, including the T670I mutant (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, due to their very low overall response rates and toxicities, the clinical application was limited. In addition, ponatinib (<b>4</b>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and cabozantinib (<b>5</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> were also reported to be capable of overcoming the T670I mutant-induced resistance (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Axitinib (<b>6</b>),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> an approved drug for renal cell carcinoma, is an orally available multitarget kinase inhibitor that potently inhibits c-KIT, PDGFRα/β, and vascular endothelial growth factor receptor (VEGFR)1/2/3 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The kinase-profiling data also revealed that it has strong binding affinity to c-KIT (binding <i>K</i><sub>d</sub>: 3.7 nM) and c-KIT V559D/T670I (binding <i>K</i><sub>d</sub>: 13 nM).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, although compounds <b>2</b>–<b>6</b> could overcome the c-KIT T670I mutant, none of them could achieve the selectivity between the c-KIT wild-type (wt) and T670I mutant. Given the fact that c-KIT wt plays important roles in normal physiological functions, inhibitors that are selectively potent to the c-KIT mutant over c-KIT wt would provide a potentially better therapeutic window. This concept has been successfully demonstrated by the third generation epidermal growth factor receptor (EGFR) inhibitor osimertinib, which selectively inhibits the EGFR T790M mutant over the EGFR wt.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> On the basis of the binding conformation of kinases, kinase inhibitors can be categorized as type I binding mode, which features a DFG-in kinase active conformation and type II binding mode, which characterizes a DFG-out kinase inactive conformation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Considering the potential chemical spaces for structure–activity relationship (SAR) exploration, the c-KIT wt/T670I dual inhibitor <b>6</b> was chosen as a starting point for further medicinal chemistry study. Through a fragment hybrid type II kinase inhibitor design approach,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> we have discovered a novel type II c-KIT kinase inhibitor compound <b>24</b> (CHMFL-KIT-033), which not only overcomes the c-KIT T670I mutant but also achieves 12-fold selectivity over the c-KIT wt (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative c-KIT kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design Rationale and Structure–Activity Relationship (SAR) Exploration</h3><div class="NLM_p">Currently there is no available X-ray crystal structure of compound <b>6</b> in complex with c-KIT kinase. On the basis of the published X-ray crystal structure of compound <b>6</b> in a complex with the ABL kinase T315I mutant (Protein Data Bank (PDB) ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TWP">4TWP</a>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> it might adopt type I binding mode with the c-KIT T670I mutant. However, on the basis of the X-ray structure of compound <b>6</b> in complex with VEGFR2 kinase (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8">4AG8</a>),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> it might adopt type II binding mode. Therefore, to better understand the binding mechanism of compound <b>6</b> to c-KIT T670I, we first docked it to the DFG-in kinase active confirmation of c-KIT T670I (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) using the Schrödinger-induced fit docking protocol. The results showed that it could fit well in the DFG-in conformation and the indazole moiety formed two hydrogen bonds with Cys673 and Glu671 in the hinge binding area (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). In addition, in the DFG-in conformation, the carbonyl group of benzamide formed a hydrogen bond with residue Asp810 in the DFG motif. Interestingly, we also found that compound <b>6</b> could fit well in the DFG-out kinase inactive conformation of c-KIT T670I (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). In the DFG-out conformation, the NH of benzamide formed a hydrogen bond with Glu640 located in the αC-Helix. Considering that both c-KIT kinase and VEGFR2 kinase belong to type III receptor tyrosine kinase family and share better structural similarity, we were prone to think that compound <b>6</b> adopted type II binding mode with c-KIT kinase. In addition, by comparing these two binding modes, we envisioned that there was limited space for affinity and selectivity improvement from type I binding mode. Given the bulky size of Ile670 residue, the inhibitor might need a more flexible linkage moiety. Meanwhile, the amino acid residues around the hydrophobic pocket that are generated by DFG-out shifting (shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C) are not conserved among different kinases and thus can serve as good factors to trim the selectivity for the type II inhibitors. Therefore, exploration of the type II binding mode, which further modifies the “linker” and “tail” moieties, might achieve the binding affinity and selectivity against the c-KIT T670I mutant. On the basis of this assumption, using the fragment hybrid type II kinase inhibitor design approach, we first designed compound <b>7</b> by replacing the thiol linkage in compound <b>6</b> with the malonamide, which presumably would provide more space to accommodate the larger isoleucine residue, and then docked it to the DFG-out conformation of c-KIT T670I (generated from PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). As expected, the docking results demonstrated that compound <b>7</b> prefers to adopt a typical type II binding mode that features two canonical hydrogen bonds formed between Glu640 and Asp810 with the amide in the linker. The indazole core forms two hydrogen bonds with Cys673 and Glu671 in the hinge binding area, and the tail moiety 4-chloro-3-trifloromethylphenyl occupies the hydrophobic pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E). The “head” moiety vinylpyridine occupies the shallow hydrophobic groove adjacent to the hinge binding area (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>F). On the basis of these analyses and the fragment hybrid type II kinase inhibitor design approach,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> we started to explore the SAR by varying the head, linker, and tail moieties meanwhile keeping the indazole core scaffold of compound <b>7</b>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of the SAR exploration rationale. (A) Type I binding mode of compound <b>6</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). (B) Type II binding mode of compound <b>6</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (C) Surface illustration of the hydrophobic pocket created by the DFG-out flip of c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (D) Binding mode of compound <b>7</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (E) Surface illustration of the hydrophobic pocket created by the DFG-out flip of c-KIT T670I. (F) Surface illustration of the shallow hydrophobic groove adjacent to the hinge binding area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We used the proliferation of IL-3 independent BaF3 cells expressing the c-KIT wt (BaF3-tel-c-KIT) and c-KIT T670I (BaF3-tel-c-KIT-T670I) as the primary readout to evaluate the compound’s activity and selectivity. As the starting point, we first explored the SAR of the linker part (L). Replacement of the phenyl thiol ether linkage with malonamide linkage (<b>7</b>) resulted in improved potency against both c-KIT wt (GI<sub>50</sub>: 0.025 μM) and c-KIT T670I (GI<sub>50</sub>: 0.002 μM) compared with compound <b>6</b>, meanwhile exhibiting 12-fold selectivity between c-KIT T670I and c-KIT wt (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, there is also a good selectivity window over the parental BaF3 cells (GI<sub>50</sub>: 7.4 μM), indicating a good on-target antiproliferative inhibition effect in the c-KIT wt and c-KIT T670I-transformed BaF3 cells. This result indicated that the design approach of type II kinase inhibitor from compound <b>6</b> was valid. However, all shorter linkers, such as amide (<b>8</b>), ethyleneamide (<b>9</b>), and urea (<b>10</b>), resulted in activity loss against c-KIT T670I. Restoring the length of the linker but increasing the size by adding the cyclopropyl group to the linker (<b>11</b>) also led to activity loss to both c-KIT wt and c-KIT T670I.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the Linker Moiety (L)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">We then fixed the linker moiety as malonamide and explored the head moiety R<sup>1</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Replacement of the vinylpyridine of <b>7</b> with hydrogen (<b>12</b>) and methyl group (<b>13</b>) both led to significant activity loss. However, 1-methyl-1<i>H</i>-pyrazole (<b>14</b>), pyridine (<b>15</b>), and 2-methylpyridine (<b>16</b>) all resulted in good inhibitory activities against c-KIT T670I (GI<sub>50</sub>: 0.023, 0.045, and 0.059 μM, respectively) meanwhile achieving the selectivity of c-KIT T670I over c-KIT wt ranging from 7- to 15-fold. This indicated that the aromatic moieties in the head region played an important role for the binding with c-KIT kinase. Changing the R<sup>1</sup> moiety from the pyridine in <b>15</b> to 5-(methylcarbamoyl)pyridin (<b>17</b>), fluorophenyl (<b>18</b>), and 3-carbamoylphenyl (<b>19</b>) led to activity loss against c-KIT wt and c-KIT T670I. <i>N</i>-Methyl formamyl (<b>20</b>) at R<sup>1</sup> also exhibited good activity against c-KIT T670I (GI<sub>50</sub>: 0.057 μM) and 6-fold selectivity over c-KIT wt. Both larger groups, such as 4-<i>N</i>-methyl piperazine (<b>21</b>) and <i>N</i>-methyl piperazinyl methylene (<b>22</b>) groups, resulted in much more potent activity against c-KIT T670I and c-KIT wt but also exhibited inhibitory activity to parental BaF3 cells. All of these results indicated that the vinylpyridine moiety at the R<sup>1</sup> position (as in compound <b>7</b>) was preferred because it exhibited the best potency against c-KIT T670I and better selectivity over c-KIT wt.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the Head Moiety (R<sup>1</sup>)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">We next explored the tail (R<sup>2</sup>) moiety by fixing the head as vinylpyridine and linker as malonamide (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Replacement of the R<sup>2</sup> moiety in compound <b>7</b> with a simple phenyl group (<b>23</b>) resulted in significant activity loss against c-KIT T670I (GI<sub>50</sub>: 0.117 μM) but exhibited selectivity over c-KIT wt (19-fold). Encouraged by this result, we tried a series of <i>meta</i>-halogen-substituted phenyl groups at R<sup>2</sup> to increase the hydrophobicity (<b>24</b>–<b>26</b>) and <i>m</i>-fluoro (<b>24</b>) exhibited the best potency against c-KIT T670I (GI<sub>50</sub>: 0.044 μM) as well as the best selectivity over c-KIT wt (26-fold). Subsequently, we tested a series of larger substituent groups, such as <i>m</i>-methyl (<b>27</b>), <i>m</i>-methoxyl (<b>28</b>), <i>m</i>-<i>N</i>,<i>N</i>-dimethyl (<b>29</b>), and <i>m</i>-trifluoromethyl (<b>30</b>). However, all of them exhibited decreased activity to c-KIT T670I and lower selectivity over c-KIT wt. The even larger group <i>m</i>-<i>N</i>-methyl piperazinyl (<b>31</b>) resulted in significant activity loss. Since <i>m</i>-fluorobenzene moiety at R<sup>2</sup> displayed the best activity, we also tried a series of fluoro-containing groups, such as <i>o</i>-fluoro (<b>32</b>), <i>p</i>-fluoro (<b>33</b>), and some multifluoro substituents (<b>34</b>–<b>36</b>). However, all of them exhibited activity loss against c-KIT T670I compared with compound <b>24</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Exploration Focused on the Tail Moiety (R<sup>2</sup>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0018.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Further Biochemical and Selectivity Characterization of Compound <b>24</b></h3><div class="NLM_p">Since compound <b>24</b> displayed the best combined potency and selectivity profiles against the c-KIT wt and T670I mutant, we then further examined its activity against a panel of c-KIT mutants in the c-KIT mutant-transformed BaF3 cells (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compared with compound <b>1</b>, <b>24</b> exhibited similar activities against primary gain-of-function mutations in the juxtamembrane (JM) domain, such as V559D/A/G and L576P. Furthermore, <b>24</b> displayed 26-fold selectivity between c-KIT wt and c-KIT T670I in the BaF3 screening system compared with compound <b>6</b>. In addition, <b>24</b> exhibited better potencies against compound <b>1</b>-resistant secondary mutants, such as V654A and T670I, in the adenosine 5′-triphosphate (ATP) binding pocket. However, just like compound <b>1</b>, <b>24</b> did not show potent activities against activation loop mutations either. Comparably, compound <b>6</b> was potent against the c-KIT primary gain-of-function mutations and ATP binding pocket mutations but relatively resistant to the activation loop mutations. More importantly, there was no selectivity between the c-KIT wt and c-KIT T670I mutation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compounds <b>1</b>, <b>6</b>, and <b>24</b> against a Panel of c-KIT Mutant-Transformed BaF3 Cells<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">GI<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">mutated region</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center" char="."><b>6</b></th><th class="colsep0 rowsep0" align="center" char="."><b>24</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT</td><td class="colsep0 rowsep0" align="left">wt</td><td class="colsep0 rowsep0" align="left">0.364</td><td class="colsep0 rowsep0" align="char" char=".">0.105</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559D</td><td class="colsep0 rowsep0" align="left">juxtamembrane</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559A</td><td class="colsep0 rowsep0" align="left">juxtamembrane</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559G</td><td class="colsep0 rowsep0" align="left">juxtamembrane</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-L576P</td><td class="colsep0 rowsep0" align="left">juxtamembrane</td><td class="colsep0 rowsep0" align="left">0.115</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.157</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V654A/V559D</td><td class="colsep0 rowsep0" align="left">ATP binding pocket</td><td class="colsep0 rowsep0" align="left">1.57</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.265</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V654A</td><td class="colsep0 rowsep0" align="left">ATP binding pocket</td><td class="colsep0 rowsep0" align="left">2.30</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.525</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-T670I</td><td class="colsep0 rowsep0" align="left">ATP binding pocket</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.108</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-T670I/V559D</td><td class="colsep0 rowsep0" align="left">ATP binding pocket</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.129</td><td class="colsep0 rowsep0" align="char" char=".">0.122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D816V</td><td class="colsep0 rowsep0" align="left">activation loop</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td><td class="colsep0 rowsep0" align="char" char=".">3.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D816H</td><td class="colsep0 rowsep0" align="left">activation loop</td><td class="colsep0 rowsep0" align="left">0.823</td><td class="colsep0 rowsep0" align="char" char=".">1.82</td><td class="colsep0 rowsep0" align="char" char=".">6.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D820E</td><td class="colsep0 rowsep0" align="left">activation loop</td><td class="colsep0 rowsep0" align="left">0.267</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.868</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-N822K</td><td class="colsep0 rowsep0" align="left">activation loop</td><td class="colsep0 rowsep0" align="left">1.29</td><td class="colsep0 rowsep0" align="char" char=".">1.72</td><td class="colsep0 rowsep0" align="char" char=".">6.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-A829P</td><td class="colsep0 rowsep0" align="left">activation loop</td><td class="colsep0 rowsep0" align="left">0.406</td><td class="colsep0 rowsep0" align="char" char=".">0.406</td><td class="colsep0 rowsep0" align="char" char=".">6.00</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div></div><div class="NLM_p">We then used the Z′-LYTE-based biochemical activity assay with purified kinase proteins to confirm the inhibition activities of compound <b>24</b> against the c-KIT wt and c-KIT T670I kinases. The results showed that <b>24</b> inhibited the c-KIT T670I kinase with an IC<sub>50</sub> of 45 nM and inhibited the c-KIT wt kinase with an IC<sub>50</sub> of 536 nM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Compound <b>24</b> exhibited about 12-fold selectivity against c-KIT T670I over c-KIT wt. To further confirm this selectivity in cells, we proceeded to examine the phosphorylation of c-KIT at Y703, 719, and 823 sites in the colon cancer cell line COLO320DM that expresses c-KIT wt kinase. As expected, <b>24</b> did not apparently affect all of these three phosphorylation sites up to 1 μM (EC<sub>50</sub>s: >1 μM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Similarly, in the c-KIT wt-transformed BaF3 cells, <b>24</b> did not affect these c-KIT phosphorylation sites up to 1 μM (EC<sub>50</sub>s: >1 μM) either (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). However, in the c-KIT T670I-transformed BaF3 cells, <b>24</b> could potently inhibit the phosphorylation of c-KIT at Y703, Y719, and Y823 sites (EC<sub>50s</sub>: 77, 750, and 34 nM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). The results demonstrated that both at a protein level and a cellular level, <b>24</b> could achieve the selectivity between c-KIT wt and c-KIT T670I, which further confirmed the selective antiproliferative effects observed from the transformed BaF3 cells.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Z′-LYTE biochemical kinase assay characterization of compound <b>24</b> against c-KIT wt/T670I kinases. (B) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT wt in the colon cancer cell line COLO320DM. (C) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT wt in BaF3-tel-c-KIT cells. (D) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT T670I in BaF3-tel-c-KIT-T670I cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further characterize the selectivity of compound <b>24</b> among other protein kinases, we examined its kinome-wide selectivity profile with DiscoverX’s KINOMEscan binding technology<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The results demonstrated that <b>24</b> bore a good selectivity (<i>S</i> score (1) = 0.02) in a panel of 468 kinases and mutants at 1 μM concentration (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Besides high binding affinity to c-KIT kinase, it also displayed strong binding to CSF1R, CSNK1A1, NEK, PAK2, PDGFRβ, PIM, and YSK1 kinases (percent of control value less than 1% at 1 μM. For further details, please refer to <a href="https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan/scanelect" class="extLink">https://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan/scanelect</a>) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf" class="ext-link">Supplementary Table 1</a>). In addition, among the c-KIT mutant panel in the assay, <b>24</b> exhibited strong binding to c-KIT L576P, V559D, V559D/T670I, and V559D/V654A (%Ctrl value less than 1% at 1 μM), which was consistent with the results observed from the transformed BaF3 cells in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Given the fact that KINOMEscan is a binding assay, which sometimes may not reflect the real inhibitory activity of the compound, we also used the Z′-LYTE activity-based assay to test the inhibitory activity of <b>24</b> against these potential targets revealed by KINOMEscan assay. The data showed that <b>24</b> could also potently inhibit CSF1R kinase (IC<sub>50</sub> = 14.2 nM) besides c-KIT T670I (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). This could be explained by both c-KIT T670I and CSF1R belonging to the type III receptor tyrosine kinase family and the ATP pocket of these two kinases being highly conserved. Interestingly, <b>24</b> did not show potent inhibitory activity against other targets from KINOMEscan assay, such as CSNK1A1, NEK1, PAK2, PDGFR, PIM3, and STK25, indicating that <b>24</b> was only selectively potent toward c-KIT T670I mutant and CSF1R kinase.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity profiling of compound <b>24</b>. (A) KINOMEscan profiling of <b>24</b> at a concentration of 1 μM against 468 kinases and mutants. (B, C) Z′-LYTE kinase assay of <b>24</b> against the kinase targets revealed from the KINOMEscan profiling in isogenic cell lines. The table shows the target kinases that had remaining activity of less than 1% control in the presence of 1 μM <b>24</b> and the IC<sub>50</sub> values of these kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand its binding mechanism, we then docked it into the c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) and T670I mutant kinase (generated from PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) by molecular modeling. In the c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) model, <b>24</b> adopts a canonical type II binding mode. The two nitrogen atoms of indazol form two hydrogen bonds with the c-KIT residues Cys673 and Glu671 in the hinge binding area (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). The amide in the linker moiety forms two hydrogen bonds with Glu640 located in the c-helix and Asp810 in the DFG motif. The tail part occupies the hydrophobic pocket generated by the DFG-out shifting. In the homology model of c-KIT T670I mutant, <b>24</b> adopts a similar type II binding mode. The malonamide linkage is flexible, which generates enough space to accommodate the larger residue Ile670, which could explain its potency against the T670I mutant (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). However, the modeling study from the published and homology structures could not explain the selectivity between the c-KIT wt and c-KIT T670I; we reasoned that there might be some kinetic factors that associate with T670I mutant<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> or the drug binding might induce special conformational change either in the c-KIT wt or c-KIT T670I mutant, which makes the inhibitor <b>24</b> more favorable for c-KIT T670I. All of these speculations would require further detailed kinetic and structural biology studies.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic illustration of the binding mechanism of compound <b>24</b>. (A) Binding mode of <b>24</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (B) Binding mode of <b>24</b> with c-KIT T670I (generated from PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Cell Evaluation of Compound <b>24</b></h3><div class="NLM_p">We next investigated the antiproliferative effects of compound <b>24</b> against a panel of established GIST cancer cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compound <b>24</b> was potent against GIST-T1 (c-KIT del 560–578, GI<sub>50</sub>: 0.052 μM) and moderately potent against GIST-882 (c-KIT K642E, GI<sub>50</sub>: 0.296 μM) cell lines. In the compound <b>1</b>-resistant cell line GIST-T1-T670I (c-KIT T670I, generated by CRISPR-Cas9 knock-in T670I mutant to the GIST-T1 cell line) (GI<sub>50</sub> > 10 μM), <b>24</b> displayed a GI<sub>50</sub> value of 0.288 μM. In addition, in another compound <b>1</b>-resistant cell line GIST-5R (c-KIT T670I, generated by continuous treatment of <b>1</b> and clone selection), <b>24</b> also exhibited better antiproliferative effects than <b>1</b> (GI<sub>50</sub>: 0.475 μM vs 10 μM). Neither of these two inhibitors has an effect against GIST-48B cell line that is c-KIT independent.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferative Effects of Compounds <b>1</b> and <b>24</b> against GIST Cells<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">c-KIT status</th><th class="colsep0 rowsep0" align="center">compd <b>1</b> (GI<sub>50</sub>, μM)</th><th class="colsep0 rowsep0" align="center">compd <b>24</b> (GI<sub>50</sub>, μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1</td><td class="colsep0 rowsep0" align="left">Δ560–578</td><td class="colsep0 rowsep0" align="left">0.026</td><td class="colsep0 rowsep0" align="left">0.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-882</td><td class="colsep0 rowsep0" align="left">K642E</td><td class="colsep0 rowsep0" align="left">0.058</td><td class="colsep0 rowsep0" align="left">0.296</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1-T670I</td><td class="colsep0 rowsep0" align="left">Δ560–578/T670I</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-5R</td><td class="colsep0 rowsep0" align="left">Δ560–578/T670I</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.475</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-48B</td><td class="colsep0 rowsep0" align="left">c-KIT-independent</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div></div><div class="NLM_p">We also evaluated the effect of compound <b>24</b> on the c-KIT-mediated signaling pathways in the GISTs cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). As expected, <b>24</b> potently inhibited the c-KIT autophosphorylation sites p-Y719, p-Y703, and p-Y823 and downstream signaling mediators, such as p-AKT (S473), p-ERK (T202/Y204), and p-S6 (S235/S236), starting from 0.1 μM concentration in the c-KIT growth-dependent GIST cancer cell line GIST-T1 and two compound <b>1</b>-resistant cell lines GIST-T1-T670I and GIST-5R (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Interestingly, in the GIST-T1-T670I and GIST-5R cells, compound <b>24</b> but not <b>1</b> could inhibit the phosphorylation of the signal transducer and activator of transcription 3 (STAT3) dose-dependently whereas in the GIST-T1 cells, neither <b>24</b> nor <b>1</b> could affect the phosphorylation of STAT3. In accordance with the effect of <b>24</b> on the c-KIT-mediated signaling pathways, <b>24</b> could also induce the cell cycle arrest and apoptosis dose-dependently in these cell lines (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,C).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Characterization of the cellular effects of compound <b>24</b>. (A) Effects of <b>24</b> on the c-KIT-mediated signaling transduction pathways in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 1 h of inhibitor treatment. (B) Apoptosis induction effects of <b>24</b> in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 24 h of inhibitor treatment. (C) Cell cycle arresting effects of <b>24</b> in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 24 h of inhibitor treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo PK/Pharmacodynamic (PD) Evaluation</h3><div class="NLM_p">We then examined the in vivo PK profile of compound <b>24</b> in rats and mice following intravenous (i.v.) and oral (p.o.) administration (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The results demonstrated that in rats, <b>24</b> displayed an acceptable bioavailability (<i>F</i> = 27.5%) with a relatively longer half-life (<i>T</i><sub>1/2</sub> = 4.9 h) and moderate drug exposure (AUC<sub>0–<i>t</i></sub> = 712 ng/(mL h)) with 10 mg/kg oral administration whereas in mice, <b>24</b> exhibited a bioavailability of 16.4% with good drug exposure (AUC<sub>0–<i>t</i></sub> = 1469 ng/(mL h)) and moderate half-life (<i>T</i><sub>1/2</sub> = 1.6 h). These data indicated that the oral administration of <b>24</b> was acceptable for the in vivo efficacy study.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic (PK) Study of Compound <b>24</b> on Rats and Mice<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">rats</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mice</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd <b>24</b></th><th class="colsep0 rowsep0" align="center" char="±">i.v. (1 mg/kg)</th><th class="colsep0 rowsep0" align="center">p.o. (10 mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">i.v. (1 mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">p.o. (10 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (ng/(mL h))</td><td class="colsep0 rowsep0" align="char" char="±">258.9 ± 30.6</td><td class="colsep0 rowsep0" align="left">712.5 ± 172.5</td><td class="colsep0 rowsep0" align="char" char=".">897.9</td><td class="colsep0 rowsep0" align="char" char=".">1468.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng/(mL h))</td><td class="colsep0 rowsep0" align="char" char="±">307.2 ± 27.1</td><td class="colsep0 rowsep0" align="left">808.9 ± 46.8</td><td class="colsep0 rowsep0" align="char" char=".">901.4</td><td class="colsep0 rowsep0" align="char" char=".">1478.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">0.017 ± 0</td><td class="colsep0 rowsep0" align="left">1.7 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">10.4 ± 1.5</td><td class="colsep0 rowsep0" align="left">4.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vz (L/kg)</td><td class="colsep0 rowsep0" align="char" char="±">49.3 ± 10.3</td><td class="colsep0 rowsep0" align="left">86.8 ± 11.8</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">19.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLz (L/(h kg))</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">12.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="±">378.5 ± 104.4</td><td class="colsep0 rowsep0" align="left">97.1 ± 27.9</td><td class="colsep0 rowsep0" align="char" char=".">3017.0</td><td class="colsep0 rowsep0" align="char" char=".">1124.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0–∞</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.3</td><td class="colsep0 rowsep0" align="left">5.4 ± 1.9</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>%</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left">27.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">16.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">All data were obtained by triple testing (±standard deviation) except mice.</p></div></div></div><div class="NLM_p">We also evaluated the pharmacodynamic profile of <b>24</b> in the GIST-5R mouse model at the 100 mg/(kg day) dosage for the impact on levels of p-c-KIT and downstream markers p-ERK and p-AKT (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf" class="ext-link">Supplementary Figure 1</a>). Meanwhile, we also monitored the drug concentration in the blood plasma. Following a single dose treatment, in a 2 h time course, the levels of p-c-KIT/ERK/AKT decreased to the lowest level and then started to recover. The drug concentration in the plasma reached the highest level in 30 min and then gradually decreased to basal levels in 4 h, which was correlated to the levels of phosphorylation of the signaling mediators.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacodynamic effects of compound <b>24</b> on p-c-KIT, p-ErK, and p-AKT in a tumor from the GIST-5R xenograft mouse model with a single dosage of 100 mg/(kg day) p.o. administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, the in vivo antitumor efficacy of compound <b>24</b> was evaluated in the GIST-5R cell-inoculated xenograft mouse model. Upon 28 days of continuous oral gavage treatment, none of 25, 50, and 100 mg/(kg day) (QD) administrations affected the mouse body weight (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) and <b>24</b> dose-dependently inhibited the tumor growth (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). The 100 mg/(kg day) dosage achieved a tumor growth inhibition of 83% (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C,D) which was much better than that in compound <b>1</b>.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor efficacy of compound <b>24</b> in the GIST-5R xenograft mouse model. Female nu/nu mice bearing established GIST-5R tumor were treated with <b>24</b> at 25, 50, and 100 mg/(kg day) or vehicle control. Daily oral administration was initiated when GIST-5R tumors had reached a size of 200 mm<sup>3</sup>. Each group contained four animals. Data = mean ± standard error of the mean. (A) Body weight change in mice for each daily dosing group of <b>24</b> and imatinib. Initial body weight was set as 100%. (B) Tumor size measurements of GIST-5R xenograft mice after <b>24</b> and imatinib treatment. (C) Representative photographs of tumors in each group after 25, 50, and 100 mg/(kg day) of <b>24</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group in a 28 day treatment period.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Syntheses of <b>7</b>, <b>11</b>, and <b>23</b>–<b>36</b> are illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Methyl ester <b>38</b> was obtained by the amide coupling reaction of <b>37</b> with carboxylic acid. Then, hydrolysis under basic condition afforded carboxylic acid <b>39</b>. Finally, amide coupling reaction with amine and removal of the tetrahydropyranyl (THP) protective group furnished the target compounds. As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, <b>8</b> and <b>9</b> were obtained from amide coupling reaction of <b>37</b> with carboxylic acid followed by deprotection of the THP group. To obtain <b>10</b>, <b>37</b> was first converted to urea and then the THP protective group was removed. In <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, Suzuki coupling reaction of <b>40</b> with arylboronic acid and protection of <b>41</b> with THP group afforded intermediate <b>42</b>. Then, the nitro group was reduced to provide amine <b>43</b>. Coupling reaction of <b>44</b> with methyl hydrogen malonate followed by hydrolysis of methyl ester <b>45</b> offered carboxylic acid <b>46</b>. The final compounds <b>12</b>–<b>22</b> were obtained by amide coupling reaction of <b>43</b> with <b>46</b> and removal of the THP protective group.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>7</b>, <b>11</b>, and <b>23</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl hydrogen malonate or 1,1-yclopropanedicarboxylic acid monomethyl ester, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate (HATU), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF), room temperature (rt), 2 h; (b) LiOH, MeOH, H<sub>2</sub>O, rt, 6 h; (c) R<sup>1</sup>NH<sub>2</sub>, HATU, DIPEA, DMF, rt, 2 h; (d) CF<sub>3</sub>COOH, dichloromethane (DCM), rt, 4 h.</p></p></figure><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Compounds <b>8</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-3-(trifluoromethyl)benzoic acid or 4-chloro-3-(trifluoromethyl)phenylacetic acid, HATU, DIPEA, DMF, rt, 2 h; (b) CF<sub>3</sub>COOH, DCM, rt, 4 h; (c) 4-chloro-3-(trifluoromethyl)phenyl isocyanate, DCM, rt, 8 h.</p></p></figure><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Compounds <b>12</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) arylboronic acid, Pd(Ph<sub>3</sub>P)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, reflux, 12 h; (b) dihydropyran, CH<sub>3</sub>SO<sub>3</sub>H, tetrahydrofuran (THF), reflux, 8 h; (c) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 20 h; (d) methyl hydrogen malonate, HATU, DIPEA, DMF, rt, 2 h; (e) LiOH, MeOH, H<sub>2</sub>O, rt, 6 h. (f) HATU, DIPEA, DMF, rt, 2 h; (g) CF<sub>3</sub>COOH, DCM, rt, 4 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38478" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38478" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, starting from a type I multiple kinase inhibitor <b>6</b> which displayed moderate c-KIT wt and c-KIT T670I dual inhibitory effects, through the fragment hybrid drug design approach, we discovered a novel indazole scaffold-based c-KIT T670I mutant selective type II kinase inhibitor <b>24</b>. In the purified protein biochemical assay, transformed BaF3 cell growth inhibition assay and in cell on-target phosphorylation assay, <b>24</b> achieved 10–30-fold selectivity between c-KIT T670I and c-KIT wt. In addition, it also displayed a great selectivity profile over other protein kinases in the kinome except CSF1R kinase. <b>24</b> exhibited a potent antiproliferative effect against imatinib-sensitive GIST cell line GIST-T1 and imatinib-resistant cell lines GIST-T1-T670I and GIST-5R through potent inhibition of the c-KIT-mediated signaling pathways, arrest of the cell cycle progression, and induction of apoptosis. Furthermore, <b>24</b> displayed a suitable PK profile and potent in vivo antitumor efficacy. Although the selectivity mechanism of the inhibitor between the c-KIT T670I mutant and c-KIT wt remains to be elucidated, the high selectivity in cell and in vivo properties of <b>24</b> might make it a useful pharmacological tool for the c-KIT wt/mutants associated physiological and pathological studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p last">All reagents and solvents were purchased from commercial sources and were used as received unless specified otherwise, or prepared as described in the literature. All moisture sensitive reactions were carried out using dry solvents under an ultrapure argon protection. Glassware was dried in an oven at 140 °C for at least 12 h prior to use and then assembled quickly while hot, sealed with rubber septa, and allowed to cool under a stream of argon. Reactions were stirred magnetically using Teflon-coated magnetic stirring bars. Commercially available disposable syringes were used for transferring the reagents and solvents. Liquid chromatography (LC)/mass spectrometry (MS) were performed on an Agilent 6224 TOF using an electrospray ionization (ESI) source coupled to an Agilent 1260 Infinity high-performance LC (HPLC) system operating in reverse mode with an Agilent XDB-C18 column (4.6 × 50 mm<sup>2</sup>, 1.8 μM) using a water/acetonitrile (each with 0.2% (v/v) formic acid) gradient at a flow rate at 0.5 mL/min. <sup>1</sup>H and <sup>13</sup>C spectra were recorded with a Bruker 400 or 850 MHz NMR spectrometer. Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet and m, multiplet. Flash column chromatography was conducted using silica gel (Silicycle 40–64 μM). The purities of all final compounds were determined to be above 95% by HPLC.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>E</i>)-<i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>7</b>)</h3><div class="NLM_p">To a solution of <b>38a</b> (30 mg, 0.07 mmol) in DMF (5 mL) were added 4-chloro-3-(trifluoromethyl)aniline (15.6 mg, 0.08 mmol), HATU (41.8 mg, 0.11 mmol), and DIEPA (18.1 mg, 0.14 mmol). The resulting mixture was stirred at room temperature for 2 h. Then, it was diluted with EtOAc (50 mL) and washed with water (100 mL × 3) and brine (100 mL). The organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was diluted with DCM (1 mL) and CF<sub>3</sub>COOH (0.5 mL). The reaction mixture was stirred at room temperature for 4 h, and then the pH value was adjusted to 12 with saturated sodium bicarbonate. The mixture was extracted by EtOAc (50 mL) and washed with water (50 mL × 2) followed by brine (50 mL). The organic layers were dried over sodium sulfate and then filtered, concentrated, and purified by silica gel column chromatography (eluting with 0–5% MeOH in DCM) to afford <b>7</b> as a yellow solid (17.5 mg, 53%). Yield = 48%. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>) δ 13.27 (s, 1H), 10.70 (s, 1H), 10.46 (s, 1H), 8.68 (s, 1H), 8.22 (d, <i>J</i> = 12.6 Hz, 2H), 8.14 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 (d, <i>J</i> = 16.1 Hz, 2H), 7.87 (d, <i>J</i> = 7.7 Hz, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.59 (d, <i>J</i> = 16.4 Hz, 1H), 7.42 (s, 1H), 7.26 (d, <i>J</i> = 7.9 Hz, 1H), 3.59 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.63, 165.81, 155.46, 149.96, 142.35, 142.22, 138.86, 137.86, 137.36, 132.72, 129.23, 127.12, 124.69, 124.54, 124.34, 123.00, 122.85, 121.51, 118.17, 117.63, 115.11, 99.74, 46.64; LC/MS (ESI, <i>m</i>/<i>z</i>) 500.11 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>8–9</b> and <b>11–36</b> were prepared following the synthetic procedure of compound <b>7</b>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>E</i>)-4-Chloro-<i>N</i>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)-3-(trifluoromethyl)benzamide (<b>8</b>)</h3><div class="NLM_p last">Yield = 52%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.23 (s, 1H), 10.71 (s, 1H), 8.63–8.58 (m, 1H), 8.44 (s, 1H), 8.33–8.26 (m, 2H), 8.19 (d, <i>J</i> = 8.7 Hz, 1H), 7.99–7.91 (m, 2H), 7.82 (td, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.68 (d, <i>J</i> = 8.7 Hz, 1H), 7.59–7.55 (m, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 1H), 7.28 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.94, 155.49, 150.00, 142.28, 142.23, 137.68, 137.32, 134.63, 134.42, 133.92, 132.42, 129.35, 127.62, 127.03, 124.65, 122.99, 122.86, 122.05, 121.35, 118.03, 116.23, 101.26; LC/MS (ESI, <i>m</i>/<i>z</i>) 443.09 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>E</i>)-2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)acetamide (<b>9</b>)</h3><div class="NLM_p last">Yield = 55%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.12 (s, 1H), 10.45 (s, 1H), 8.62–8.56 (m, 1H), 8.13 (t, <i>J</i> = 2.0 Hz, 1H), 8.12 (d, <i>J</i> = 8.8 Hz, 1H), 7.94–7.88 (m, 1H), 7.87 (d, <i>J</i> = 1.7 Hz, 1H), 7.81 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.67 (dd, <i>J</i> = 14.0, 4.8 Hz, 2H), 7.55–7.51 (m, 1H), 7.29–7.21 (m, 2H), 3.86 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.04, 155.47, 149.99, 142.33, 142.20, 137.97, 137.34, 136.43, 135.64, 131.96, 129.41, 129.24, 126.85, 124.66, 124.45, 122.98, 122.85, 122.31, 121.47, 117.57, 115.19, 99.75, 42.42; LC/MS (ESI, <i>m</i>/<i>z</i>) 457.11 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>E</i>)-1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)urea (<b>10</b>)</h3><div class="NLM_p last">To a solution of <b>37</b> (20 mg, 0.06 mmol) in DCM (20 mL) was added 4-chloro-3-(trifluoromethyl)phenyl isocyanate (13.8 mg, 0.06 mmol). The resulting mixture was stirred at room temperature for 8 h and then concentrated to dryness. The residue was diluted with DCM (1 mL) and CF<sub>3</sub>COOH (0.5 mL). The reaction mixture was stirred at room temperature for 4 h, and then the pH value was adjusted to 12 with saturated sodium bicarbonate. The mixture was extracted by EtOAc (50 mL) and washed with water (50 mL × 2) followed by brine (50 mL). The organic layers were dried over sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluting with 0–5% MeOH in DCM) to afford <b>10</b> as a yellow solid (17 mg, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.09 (s, 1H), 9.41 (s, 1H), 9.29 (s, 1H), 8.62 (s, 1H), 8.17 (s, 1H), 8.09 (d, <i>J</i> = 7.9 Hz, 1H), 7.98 (s, 1H), 7.92 (d, <i>J</i> = 16.5 Hz, 1H), 7.81 (d, <i>J</i> = 6.9 Hz, 1H), 7.73–7.59 (m, 3H), 7.54 (d, <i>J</i> = 16.4 Hz, 1H), 7.28 (s, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.52, 153.06, 149.99, 142.70, 142.11, 139.87, 138.42, 137.32, 132.46, 129.15, 127.27, 124.69, 124.29, 123.60, 122.94, 122.82, 122.22, 121.42, 117.27, 117.00, 115.14, 98.69; LC/MS (ESI, <i>m</i>/<i>z</i>) 458.10 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>E</i>)-<i>N</i>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)cyclopropane-1,1-dicarboxamide (<b>11</b>)</h3><div class="NLM_p last">Yield = 53%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.22 (s, 1H), 10.45 (s, 1H), 10.25 (s, 1H), 8.63 (s, 1H), 8.29 (s, 1H), 8.15 (s, 1H), 8.11 (d, <i>J</i> = 8.3 Hz, 1H), 7.96 (d, <i>J</i> = 15.8 Hz, 2H), 7.88 (s, 1H), 7.75 (s, 1H), 7.68 (d, <i>J</i> = 8.9 Hz, 1H), 7.56 (d, <i>J</i> = 16.7 Hz, 1H), 7.39–7.30 (m, 2H), 1.51 (s, 4H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.26, 168.28, 154.93, 148.96, 142.18, 141.92, 139.01, 138.36, 137.94, 132.35, 127.95, 127.03, 126.73, 126.71, 125.71, 125.54, 124.60, 124.35, 123.09, 122.22, 121.73, 121.04, 119.60, 119.55, 117.71, 116.35, 115.38, 101.14, 32.88, 15.85; LC/MS (ESI, <i>m</i>/<i>z</i>) 526.13 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(1<i>H</i>-indazol-6-yl)malonamide (<b>12</b>)</h3><div class="NLM_p last">Yield = 53%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.91 (s, 1H), 10.66 (s, 1H), 10.34 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 7.97 (s, 1H), 7.86 (d, <i>J</i> = 8.8 Hz, 1H), 7.73–7.64 (m, 2H), 7.09 (d, <i>J</i> = 8.6 Hz, 1H), 3.55 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.67, 165.70, 140.76, 138.84, 137.49, 133.80, 132.71, 127.36, 124.34, 122.08, 121.22, 119.73, 118.17, 114.42, 99.41, 46.59. LC/MS (ESI, <i>m</i>/<i>z</i>) 397.07 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-methyl-1<i>H</i>-indazol-6-yl)malonamide (<b>13</b>)</h3><div class="NLM_p last">Yield = 46%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.47 (s, 1H), 10.65 (s, 1H), 10.30 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 8.05 (d, <i>J</i> = 1.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.69 (d, <i>J</i> = 8.8 Hz, 1H), 7.61 (d, <i>J</i> = 8.6 Hz, 1H), 7.06 (dd, <i>J</i> = 8.6, 1.6 Hz, 1H), 3.55 (s, 2H), 2.44 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.69, 165.64, 141.67, 141.40, 138.84, 137.51, 132.70, 127.32, 124.33, 122.01, 120.64, 119.10, 118.12, 113.51, 99.39, 46.59, 12.11; LC/MS (ESI, <i>m</i>/<i>z</i>) 411.09 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indazol-6-yl)malonamide (<b>14</b>)</h3><div class="NLM_p last">Yield = 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.81 (s, 1H), 10.80 (s, 1H), 10.47 (s, 1H), 8.33 (s, 1H), 8.23 (s, 1H), 8.13 (s, 1H), 7.96 (s, 2H), 7.87 (s, 1H), 7.71 (s, 1H), 7.15 (s, 1H), 3.92 (s, 3H), 3.56 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 165.73, 142.00, 138.90, 137.85, 137.73, 136.85, 132.69, 128.77, 127.16, 124.51, 124.35, 122.09, 121.19, 118.18, 116.96, 115.41, 114.38, 99.56, 46.64, 39.06; LC/MS (ESI, <i>m</i>/<i>z</i>) 477.11 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(pyridin-3-yl)-1<i>H</i>-indazol-6-yl)malonamide (<b>15</b>)</h3><div class="NLM_p last">Yield = 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.29 (s, 1H), 10.70 (s, 1H), 10.46 (s, 1H), 9.19 (s, 1H), 8.63–8.56 (m, 1H), 8.37–8.33 (m, 1H), 8.23 (s, 2H), 8.08–8.03 (m, 1H), 7.89–7.84 (m, 1H), 7.73–7.66 (m, 1H), 7.58–7.50 (m, 1H), 7.28–7.19 (m, 1H), 3.58–3.57 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.73, 165.95, 158.80, 148.81, 147.47, 142.60, 140.73, 138.75, 137.82, 134.51, 132.68, 130.09, 127.15, 124.57, 124.36, 121.23, 118.77, 118.15, 116.97, 116.46, 115.48, 99.88, 46.10; LC/MS (ESI, <i>m</i>/<i>z</i>) 474.10 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(6-methylpyridin-3-yl)-1<i>H</i>-indazol-6-yl)malonamide (<b>16</b>)</h3><div class="NLM_p last">Yield = 57%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.21 (s, 1H), 10.68 (s, 1H), 10.43 (s, 1H), 9.05 (s, 1H), 8.23–8.21 (m, 3H), 8.01 (s, 1H), 7.86 (s, 1H), 7.71 (s, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (s, 1H), 3.58 (s, 2H), 2.55 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 488.11 [M + H]<sup>+</sup>.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(5-(methylcarbamoyl)pyridin-3-yl)-1<i>H</i>-indazol-6-yl)malonamide (<b>17</b>)</h3><div class="NLM_p last">Yield = 39%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.40 (s, 1H), 10.70 (s, 1H), 10.48 (s, 1H), 9.29 (s, 1H), 9.00 (s, 1H), 8.82 (s, 1H), 8.68 (s, 1H), 8.23 (s, 2H), 8.12 (s, 1H), 7.86 (s, 1H), 7.70 (s, 1H), 7.25 (s, 1H), 3.58 (s, 2H), 2.85 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 531.12 [M + H]<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(3-fluorophenyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>18</b>)</h3><div class="NLM_p last">Yield = 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.25 (s, 1H), 10.71 (s, 1H), 10.47 (s, 1H), 8.23 (s, 2H), 8.05 (d, <i>J</i> = 7.2 Hz, 1H), 7.85 (s, 2H), 7.71 (s, 2H), 7.56 (s, 1H), 7.22 (s, 2H), 3.57 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.63, 165.85, 163.97, 162.04, 142.65, 142.31, 138.84, 137.77, 136.54, 132.71, 131.42, 127.18, 124.35, 123.11, 121.40, 118.13, 116.85, 115.42, 114.78, 113.45, 113.27, 99.73, 46.62; LC/MS (ESI, <i>m</i>/<i>z</i>) 491.09 [M + H]<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i><sup>1</sup>-(3-(3-Carbamoylphenyl)-1<i>H</i>-indazol-6-yl)-<i>N</i><sup>3</sup>-(4-chloro-3-(trifluoromethyl)phenyl)malonamide (<b>19</b>)</h3><div class="NLM_p last">Yield = 37%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.20 (s, 1H), 10.73 (s, 1H), 10.48 (s, 1H), 8.43 (s, 1H), 8.23 (s, 2H), 8.14 (s, 2H), 8.04 (s, 1H), 7.88 (s, 1H), 7.71 (s, 1H), 7.59 (s, 1H), 7.48 (s, 1H), 7.17–7.16 (m, 2H), 3.59 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 516.11 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(4-(methylcarbamoyl)phenyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>20</b>)</h3><div class="NLM_p last">Yield = 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.24 (s, 1H), 10.72 (s, 1H), 10.47 (s, 1H), 8.52 (s, 1H), 8.23 (s, 2H), 8.07 (s, 3H), 7.98 (s, 2H), 7.89 (s, 1H), 7.71 (s, 1H), 7.25 (s, 1H), 3.59 (s, 2H), 2.83 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 530.12 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>21</b>)</h3><div class="NLM_p last">Yield = 41%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.90 (s, 1H), 10.70 (s, 1H), 10.41 (s, 1H), 8.23 (s, 1H), 8.15 (s, 1H), 7.95 (d, <i>J</i> = 9.0 Hz, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 4H), 7.70 (d, <i>J</i> = 8.7 Hz, 1H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.07 (d, <i>J</i> = 8.8 Hz, 2H), 3.50 (s, 2H), 2.35 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 572.19 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i><sup>1</sup>-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i><sup>3</sup>-(3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>22</b>)</h3><div class="NLM_p last">Yield = 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.09 (s, 1H), 10.75 (s, 1H), 10.46 (s, 1H), 8.24 (s, 1H), 8.19 (s, 1H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 7.6 Hz, 2H), 7.88 (d, <i>J</i> = 7.0 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (d, <i>J</i> = 7.3 Hz, 2H), 7.22 (d, <i>J</i> = 7.7 Hz, 1H), 3.58 (d, <i>J</i> = 6.8 Hz, 4H), 2.68 (s, 4H), 2.51 (s, 4H), 2.40 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 585.20 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>E</i>)-<i>N</i><sup>1</sup>-Phenyl-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>23</b>)</h3><div class="NLM_p last">Yield = 58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.42 (s, 1H), 10.22 (s, 1H), 8.61 (s, 1H), 8.20 (s, 1H), 8.14 (s, 1H), 7.92 (d, <i>J</i> = 16.5 Hz, 1H), 7.82 (s, 1H), 7.65–7.63 (m, 3H), 7.55 (d, <i>J</i> = 16.3 Hz, 1H), 7.32–7.30 (m, 4H), 7.08 (s, 1H), 3.55 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.60, 165.80, 163.96, 163.84, 162.03, 161.91, 155.12, 149.42, 141.89, 137.88, 128.50, 123.09, 123.01, 121.47, 117.64, 115.20, 102.53, 102.29, 99.68, 99.01, 46.68; LC/MS (ESI, <i>m</i>/<i>z</i>) 398.16 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-Fluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>24</b>)</h3><div class="NLM_p last">Yield = 56%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.44 (d, <i>J</i> = 9.1 Hz, 2H), 8.61 (d, <i>J</i> = 4.3 Hz, 1H), 8.20 (s, 1H), 8.14 (d, <i>J</i> = 8.7 Hz, 1H), 7.92 (d, <i>J</i> = 16.4 Hz, 1H), 7.81 (t, <i>J</i> = 7.6 Hz, 1H), 7.69–7.60 (m, 2H), 7.55 (d, <i>J</i> = 16.4 Hz, 1H), 7.36 (dt, <i>J</i> = 23.1, 7.9 Hz, 2H), 7.31–7.19 (m, 2H), 6.91 (t, <i>J</i> = 8.3 Hz, 1H), 3.53 (d, <i>J</i> = 29.4 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.28, 166.03, 163.58, 161.66, 155.48, 150.00, 142.36, 142.22, 141.07, 137.89, 137.34, 130.99, 129.28, 124.65, 123.00, 122.86, 121.50, 117.61, 115.32, 110.46, 106.46, 99.73, 63.88, 46.61; LC/MS (ESI, <i>m</i>/<i>z</i>) 416.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-Chlorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>25</b>)</h3><div class="NLM_p last">Yield = 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.14 (s, 1H), 10.42 (s, 2H), 8.61 (s, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.87 (dd, <i>J</i> = 33.5, 16.8 Hz, 3H), 7.66 (s, 1H), 7.59–7.43 (m, 2H), 7.37 (s, 1H), 7.27 (s, 2H), 7.15 (s, 1H), 3.55 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 432.12 [M + H]<sup>+</sup>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-Bromophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>26</b>)</h3><div class="NLM_p last">Yield = 51%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.49 (s, 2H), 8.61 (s, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.92 (d, <i>J</i> = 16.4 Hz, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.53 (s, 2H), 7.29–7.27 (m, 3H), 3.57 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 476.7 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-(2-(Pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)-<i>N</i><sup>3</sup>-(<i>m</i>-tolyl)malonamide (<b>27</b>)</h3><div class="NLM_p last">Yield = 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.17 (s, 1H), 10.43 (s, 1H), 10.16 (s, 1H), 8.62 (s, 1H), 8.21 (s, 1H), 8.17–8.11 (m, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.58–7.53 (m, 1H), 7.48 (s, 1H), 7.44–7.42 (m, 1H), 7.23 (s, 3H), 6.92–6.83 (m, 1H), 3.82–3.74 (m, 2H), 2.24 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 412.18 [M + H]<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-Methoxyphenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>28</b>)</h3><div class="NLM_p last">Yield = 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.15 (s, 1H), 10.44 (s, 1H), 10.24 (s, 1H), 8.61 (s, 1H), 8.20 (s, 1H), 8.13 (s, 1H), 7.92 (d, <i>J</i> = 16.2 Hz, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.55 (d, <i>J</i> = 16.1 Hz, 1H), 7.34 (s, 1H), 7.25 (s, 2H), 7.17 (s, 1H), 6.67 (s, 1H), 3.75 (s, 3H), 3.54 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 428.17 [M + H]<sup>+</sup>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-(Dimethylamino)phenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>29</b>)</h3><div class="NLM_p last">Yield = 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.14 (s, 1H), 10.38 (s, 1H), 10.01 (s, 1H), 8.61 (s, 1H), 8.21 (s, 1H), 8.16–8.10 (m, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.57 (s, 1H), 7.24 (s, 2H), 7.07 (s, 2H), 6.95 (s, 1H), 6.47 (s, 1H), 3.52 (s, 2H), 2.89 (s, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.35, 165.70, 155.48, 151.27, 150.00, 142.38, 142.21, 140.19, 137.96, 137.34, 129.57, 129.25, 124.67, 123.01, 122.85, 121.47, 117.56, 115.15, 108.41, 107.83, 103.63, 99.68, 46.64, 40.55; LC/MS (ESI, <i>m</i>/<i>z</i>) 441.21 [M + H]<sup>+</sup>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-(2-(Pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)-<i>N</i><sup>3</sup>-(3-(trifluoromethyl)phenyl)malonamide (<b>30</b>)</h3><div class="NLM_p last">Yield = 47%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.15 (s, 1H), 10.61 (s, 1H), 10.45 (s, 1H), 8.60 (s, 1H), 8.19 (s, 1H), 8.14 (s, 2H), 7.92 (d, <i>J</i> = 15.6 Hz, 1H), 7.81 (s, 2H), 7.66 (s, 1H), 7.55 (d, <i>J</i> = 15.9 Hz, 2H), 7.44 (s, 1H), 7.25 (s, 2H), 3.58 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.52, 165.95, 155.48, 150.00, 142.35, 142.22, 140.16, 137.89, 137.34, 130.58, 129.84, 129.27, 125.64, 124.65, 123.11, 123.01, 122.85, 121.49, 120.24, 117.61, 115.58, 115.13, 99.73, 46.63; LC/MS (ESI, <i>m</i>/<i>z</i>) 466.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>31</b>)</h3><div class="NLM_p last">Yield = 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.14 (s, 1H), 10.40 (s, 1H), 10.08 (s, 1H), 8.61 (s, 1H), 8.20 (s, 1H), 8.13 (s, 1H), 7.93 (d, <i>J</i> = 16.3 Hz, 1H), 7.81 (s, 1H), 7.67 (s, 1H), 7.55 (d, <i>J</i> = 15.4 Hz, 1H), 7.34–7.25 (m, 3H), 7.15 (s, 1H), 7.04 (s, 1H), 6.69 (s, 1H), 3.52 (s, 2H), 3.34 (s, 4H), 3.14 (s, 4H), 2.29 (s, 3H); LC/MS (ESI, <i>m</i>/<i>z</i>) 496.25 [M + H]<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>E</i>)-<i>N</i><sup>1</sup>-(2-Fluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>32</b>)</h3><div class="NLM_p last">Yield = 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.43 (s, 1H), 10.08 (s, 1H), 8.61 (s, 1H), 8.20 (s, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.92 (d, <i>J</i> = 17.2 Hz, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.55 (d, <i>J</i> = 16.9 Hz, 1H), 7.28–7.19 (m, 5H), 3.66 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.43, 166.22, 155.48, 154.67, 152.83, 150.00, 142.36, 142.21, 137.85, 137.34, 129.27, 124.89, 124.65, 123.98, 123.01, 122.85, 121.49, 117.62, 116.00, 115.85, 115.16, 99.80; LC/MS (ESI, <i>m</i>/<i>z</i>) 416.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>E</i>)-<i>N</i><sup>1</sup>-(4-Fluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>33</b>)</h3><div class="NLM_p last">Yield = 47%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.28 (s, 1H), 10.43 (s, 1H), 10.16 (s, 1H), 8.62 (s, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.43 (s, 1H), 7.23 (s, 3H), 6.92 (s, 1H), 3.46 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 416.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>E</i>)-<i>N</i><sup>1</sup>-(3,5-Difluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>34</b>)</h3><div class="NLM_p last">Yield = 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.19 (s, 1H), 10.65 (s, 1H), 10.46 (s, 1H), 8.62 (s, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 7.94 (d, <i>J</i> = 15.5 Hz, 1H), 7.86 (s, 1H), 7.72 (s, 1H), 7.56 (d, <i>J</i> = 15.8 Hz, 1H), 7.35 (s, 3H), 7.23 (s, 1H), 6.96 (s, 1H), 3.56 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 434.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>E</i>)-<i>N</i><sup>1</sup>-(2,5-Difluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>35</b>)</h3><div class="NLM_p last">Yield = 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.44 (s, 1H), 10.30 (s, 1H), 8.60 (s, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 8.00 (s, 1H), 7.92 (d, <i>J</i> = 16.3 Hz, 1H), 7.81 (s, 1H), 7.66 (s, 1H), 7.55 (d, <i>J</i> = 16.3 Hz, 1H), 7.36 (s, 1H), 7.25 (d, <i>J</i> = 18.8 Hz, 2H), 7.00 (s, 1H), 3.69 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 434.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>E</i>)-<i>N</i><sup>1</sup>-(Perfluorophenyl)-<i>N</i><sup>3</sup>-(3-(2-(pyridin-2-yl)vinyl)-1<i>H</i>-indazol-6-yl)malonamide (<b>36</b>)</h3><div class="NLM_p last">Yield = 43%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.16 (s, 1H), 10.49 (s, 1H), 10.40 (s, 1H), 8.60 (s, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 7.91 (d, <i>J</i> = 16.9 Hz, 1H), 7.81 (s, 1H), 7.66 (s, 1H), 7.55 (d, <i>J</i> = 16.2 Hz, 1H), 7.25 (d, <i>J</i> = 22.2 Hz, 2H), 3.63 (s, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 488.12 [M + H]<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl (<i>E</i>)-3-Oxo-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-yl)amino)propanoate (<b>38a</b>)</h3><div class="NLM_p">To a solution of <b>37</b> (500 mg, 1.56 mmol) in DMF (15 mL) were added methyl hydrogen malonate (240 mg, 1.88 mmol), HATU (770.6 mg, 2.03 mmol), and DIEPA (402 mg, 3.12 mmol). The resulting mixture was stirred at room temperature for 2 h. Then, it was diluted with EtOAc (100 mL) and washed with water (100 mL × 3) and brine (100 mL). The organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluting with 0–5% MeOH in DCM) to afford <b>38a</b> as a yellow solid (557 mg, 85%). Yield = 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 8.62 (s, 1H), 8.22 (s, 1H), 8.15 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (d, <i>J</i> = 16.5 Hz, 1H), 7.82 (s, 1H), 7.69 (d, <i>J</i> = 7.3 Hz, 1H), 7.58 (d, <i>J</i> = 16.4 Hz, 1H), 7.31 (d, <i>J</i> = 8.5 Hz, 2H), 5.77 (d, <i>J</i> = 6.9 Hz, 1H), 3.92 (d, <i>J</i> = 10.0 Hz, 1H), 3.69 (s, 3H), 3.56 (s, 2H), 2.43 (d, <i>J</i> = 11.1 Hz, 1H), 2.03 (s, 2H), 1.80 (s, 1H), 1.61 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.52, 164.87, 155.24, 150.03, 141.76, 141.44, 138.20, 137.37, 130.35, 123.78, 123.14, 123.06, 121.79, 119.04, 115.82, 100.14, 84.85, 67.07, 52.48, 44.07, 29.26, 25.29, 22.48; LC/MS (ESI, <i>m</i>/<i>z</i>) 421.19 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>38b</b> and <b>45</b> were prepared following the synthetic procedure of compound <b>38a</b>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Methyl (<i>E</i>)-1-((3-(2-(Pyridin-2-yl)vinyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-yl)carbamoyl)cyclopropane-1-carboxylate (<b>38b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.63 (s, 1H), 8.24 (s, 1H), 8.13 (d, <i>J</i> = 8.7 Hz, 1H), 7.92 (d, <i>J</i> = 16.4 Hz, 1H), 7.87 (t, <i>J</i> = 7.6 Hz, 1H), 7.76 (d, <i>J</i> = 7.8 Hz, 1H), 7.59 (d, <i>J</i> = 16.4 Hz, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 1H), 7.35–7.30 (m, 1H), 5.77 (d, <i>J</i> = 9.4 Hz, 1H), 3.93–39.1 (m, 1H), 3.77–3.67 (m, 4H), 2.47–2.37 (m, 1H), 2.11–1.96 (m, 2H), 1.80 (s, 1H), 1.58–1.48 (m, 2H), 1.52–1.46 (m, 2H), 1.45–1.42 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 180.42, 172.33, 166.77, 154.91, 149.37, 141.66, 141.49, 138.47, 137.98, 129.64, 124.40, 123.22, 121.62, 118.93, 116.15, 100.21, 84.79, 67.10, 52.96, 30.55, 29.27, 25.29, 22.51, 16.86, 15.61; LC/MS (ESI, <i>m</i>/<i>z</i>) 447.21 [M + H]<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>E</i>)-3-Oxo-3-((3-(2-(Pyridin-2-yl)vinyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-yl)amino)propanoic Acid (<b>39a</b>)</h3><div class="NLM_p">To a solution of <b>38a</b> (328 mg, 0.78 mmol) in THF (15 mL) were added LiOH (188 mg, 7.84 mmol) and water (15 mL). The reaction mixture was stirred at room temperature for 6 h under an argon protection. The mixture was acidified with 1 N hydrochloric acid to pH = 3. The yellow precipitate was filtered and dried to provide <b>39a</b> (245 mg, 75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 10.46 (s, 1H), 8.62 (s, 1H), 8.24 (s, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.91 (d, <i>J</i> = 16.3 Hz, 1H), 7.83 (s, 1H), 7.71 (d, <i>J</i> = 7.2 Hz, 1H), 7.59 (d, <i>J</i> = 16.3 Hz, 1H), 7.33 (d, <i>J</i> = 9.3 Hz, 2H), 5.77 (d, <i>J</i> = 8.6 Hz, 1H), 3.92 (d, <i>J</i> = 9.7 Hz, 1H), 3.73 (s, 1H), 3.45 (s, 2H), 2.44 (d, <i>J</i> = 10.5 Hz, 1H), 2.03 (s, 2H), 1.79 (s, 1H), 1.60 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.68, 165.44, 156.51, 155.09, 149.78, 141.70, 141.47, 138.37, 137.62, 130.03, 124.05, 123.17, 123.11, 121.72, 118.97, 115.86, 100.06, 84.87, 67.08, 44.59, 29.26, 25.28; LC/MS (ESI, <i>m</i>/<i>z</i>) 418.18 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>39b</b> and <b>46</b> were prepared following the synthetic procedure of compound <b>39a</b>.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>E</i>)-1-((3-(2-(Pyridin-2-yl)vinyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-yl)carbamoyl)cyclopropane-1-carboxylic Acid (<b>39b</b>)</h3><div class="NLM_p last">Yield = 74%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.92 (s, 1H), 8.78 (t, <i>J</i> = 6.2 Hz, 1H), 8.56–8.45 (m, 2H), 8.40–8.34 (m, 1H), 8.30 (s, 1H), 8.24 (t, <i>J</i> = 6.7 Hz, 1H), 7.95 (t, <i>J</i> = 12.9 Hz, 1H), 7.82 (t, <i>J</i> = 6.4 Hz, 1H), 7.45 (d, <i>J</i> = 8.8 Hz, 1H), 5.85 (d, <i>J</i> = 9.7 Hz, 1H), 3.92 (d, <i>J</i> = 11.3 Hz, 1H), 3.79–3.72 (m, 1H), 2.45–2.39 (m, 1H), 2.10–2.02 (m, 2H), 1.87–1.75 (m, 1H), 1.65–1.56 (m, 2H), 1.53–1.48 (m, 4H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.16, 167.60, 150.77, 145.24, 142.13, 141.62, 140.69, 138.54, 131.39, 125.08, 124.16, 121.44, 121.13, 118.97, 116.86, 100.47, 84.86, 67.11, 29.41, 29.23, 25.25, 22.39, 17.61; LC/MS (ESI, <i>m</i>/<i>z</i>) 433.19 [M + H]<sup>+</sup>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 6-Nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42a</b>)</h3><div class="NLM_p">To a solution of <b>41a</b> (0.50 g, 3 mmol) in anhydrous THF (10 mL) were added 3,4-dihydropyran (0.91 mL, 10 mmol) and methanesulfonic acid (0.03 g, 0.3 mmol) at 0 °C. The reaction mixture was stirred at 80 °C under an argon protection for 8 h and then cooled to room temperature before pouring into saturated sodium bicarbonate (50 mL). The mixture was extracted by EtOAc (50 mL) and washed with water (50 mL × 2) followed by brine (50 mL). The organic layers were dried over sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluting with 0–10% EtOAc in heptane) to afford <b>42a</b> as a white solid (621 mg, 81%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 8.38 (s, 1H), 8.03 (q, <i>J</i> = 8.8 Hz, 2H), 6.12 (d, <i>J</i> = 9.1 Hz, 1H), 3.95–3.82 (m, 2H), 2.43–2.30 (m, 1H), 2.13–2.00 (m, 2H), 1.82–1.73 (m, 1H), 1.62–1.56 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 145.54, 137.49, 133.65, 126.67, 121.75, 115.13, 106.53, 83.37, 65.93, 28.29, 24.16, 21.38.</div><div class="NLM_p last">Compound <b>42b</b> were prepared following the synthetic procedure of compound <b>42a</b>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-Methyl-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42b</b>)</h3><div class="NLM_p last">Yield = 74%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (s, 1H), 7.97 (s, 2H), 6.02 (dd, <i>J</i> = 9.6, 1.8 Hz, 1H), 3.87 (s, 2H), 2.51 (s, 1H), 2.42–2.33 (m, 1H), 2.05–1.94 (m, 2H), 1.79–1.70 (m, 1H), 1.65–1.56 (m, 2H), 1.52–1.41 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 145.66, 141.70, 138.31, 125.97, 121.09, 114.40, 106.26, 83.08, 66.00, 28.39, 24.18, 21.54, 11.00.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42c</b>)</h3><div class="NLM_p">To a mixture of <b>40</b> (0.75 g, 2.0 mmol) and 1,4-dioxane/H<sub>2</sub>O (20 mL, v/v, 5:1) were added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (0.50 g, 2.4 mmol), K<sub>2</sub>CO<sub>3</sub> (0.83 g, 6.0 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.23 g, 0.2 mmol). The reaction mixture was placed in an oil bath preheated to 90 °C and stirred at this temperature for 12 h under an argon protection. Then, the reaction mixture was cooled to rt before pouring into water (20 mL). The mixture was extracted by EtOAc (50 mL) and washed with water (50 mL) followed by brine (50 mL). The organic layers were dried over sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluting with 0–5% MeOH in DCM) to afford <b>42c</b> as a yellow solid (0.54 g, 83%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (s, 1H), 8.48 (s, 1H), 8.27 (d, <i>J</i> = 8.9 Hz, 1H), 8.05 (s, 1H), 8.02 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 6.11 (d, <i>J</i> = 9.3 Hz, 1H), 3.95 (s, 3H), 3.94–3.78 (m, 2H), 2.52–2.41 (m, 1H), 2.11–1.98 (m, 2H), 1.84–1.73 (m, 1H), 1.61 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 146.77, 139.65, 138.75, 137.19, 129.66, 124.66, 122.56, 116.08, 113.63, 107.64, 84.35, 67.11, 29.42, 25.19, 22.52; LC/MS (ESI, <i>m</i>/<i>z</i>) 328.14 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>42d</b>–<b>k</b> were prepared following the synthetic procedure of compound <b>42c</b>.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 6-Nitro-3-(pyridin-3-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42d</b>)</h3><div class="NLM_p last">Yield = 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.18 (s, 1H), 8.80 (s, 1H), 8.68 (s, 1H), 8.35 (s, 2H), 8.05 (s, 1H), 7.59 (s, 1H), 6.20 (s, 1H), 3.90 (s, 2H), 2.48 (s, 1H), 2.09 (s, 2H), 1.92–1.71 (m, 1H), 1.63 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.10, 148.17, 146.75, 141.59, 140.12, 134.95, 128.32, 124.74, 124.62, 122.75, 116.98, 108.05, 84.60, 67.02, 29.27, 25.15, 22.31; LC/MS (ESI, <i>m</i>/<i>z</i>) 325.13 [M + H]<sup>+</sup>.</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-(6-Methylpyridin-3-yl)-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42e</b>)</h3><div class="NLM_p last">Yield = 78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.03 (d, <i>J</i> = 17.4 Hz, 1H), 8.79 (d, <i>J</i> = 18.2 Hz, 1H), 8.25 (s, 1H), 8.03 (d, <i>J</i> = 9.5 Hz, 1H), 7.46 (s, 1H), 7.26 (s, 1H), 6.18 (s, 1H), 3.90 (s, 2H), 2.56 (d, <i>J</i> = 9.8 Hz, 4H), 2.06 (s, 2H), 1.79 (s, 1H), 1.62 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.73, 147.41, 146.57, 141.70, 140.04, 135.07, 125.49, 124.68, 123.82, 122.69, 116.79, 107.92, 84.56, 67.05, 29.28, 25.17, 24.38, 22.37; LC/MS (ESI, <i>m</i>/<i>z</i>) 339.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-Methyl-5-(6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)nicotinamide (<b>42f</b>)</h3><div class="NLM_p last">Yield = 74%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.31 (s, 1H), 9.09 (s, 1H), 8.90 (s, 1H), 8.86 (s, 1H), 8.71 (s, 1H), 8.42 (s, 1H), 8.11 (d, <i>J</i> = 9.0 Hz, 1H), 6.25 (d, <i>J</i> = 9.2 Hz, 1H), 3.98–3.85 (m, 2H), 2.87 (s, 3H), 2.53–2.49 (m, 1H), 2.11–2.09 (m, 2H), 1.85–1.78 (m, 1H), 1.64 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.10, 149.83, 148.52, 146.87, 140.98, 140.21, 133.45, 130.78, 128.14, 124.69, 122.89, 117.17, 108.15, 84.60, 67.13, 29.33, 26.75, 25.14, 22.37; LC/MS (ESI, <i>m</i>/<i>z</i>) 382.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-(3-Fluorophenyl)-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42g</b>)</h3><div class="NLM_p last">Yield = 83%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (s, 1H), 8.34 (d, <i>J</i> = 9.0 Hz, 1H), 8.06 (d, <i>J</i> = 9.0 Hz, 1H), 7.86 (d, <i>J</i> = 7.7 Hz, 1H), 7.76 (dd, <i>J</i> = 10.1, 1.2 Hz, 1H), 7.66–7.59 (m, 1H), 7.33 (td, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.20 (d, <i>J</i> = 9.2 Hz, 1H), 3.97–3.82 (m, 2H), 2.50–2.42 (m, 1H), 2.08 (d, <i>J</i> = 9.9 Hz, 2H), 1.80 (td, <i>J</i> = 15.5, 8.5 Hz, 1H), 1.65 (d, <i>J</i> = 21.4 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.92, 160.97, 145.64, 141.86, 139.16, 133.51, 130.70, 123.54, 122.68, 115.92, 114.91, 112.92, 106.98, 83.46, 65.95, 28.20, 24.10, 21.28; LC/MS (ESI, <i>m</i>/<i>z</i>) 342.13 [M + H]<sup>+</sup>.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-(6-Nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)benzamide (<b>42h</b>)</h3><div class="NLM_p last">Yield = 71%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (s, 1H), 8.45 (s, 1H), 8.35 (d, <i>J</i> = 9.0 Hz, 1H), 8.20 (s, 1H), 8.14 (d, <i>J</i> = 7.7 Hz, 1H), 8.10 (d, <i>J</i> = 8.9 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.66 (t, <i>J</i> = 7.7 Hz, 1H), 7.53 (s, 1H), 6.22 (d, <i>J</i> = 9.2 Hz, 1H), 3.90 (dt, <i>J</i> = 18.2, 11.4 Hz, 2H), 2.58–2.51 (m, 1H), 2.09–2.0 (m, 2H), 1.88–1.76 (m, 1H), 1.67–1.60 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.05, 146.73, 143.75, 140.21, 135.69, 132.38, 130.36, 129.63, 128.19, 126.60, 124.73, 122.87, 116.90, 108.01, 84.51, 67.09, 29.36, 25.17, 22.42; LC/MS (ESI, <i>m</i>/<i>z</i>) 367.14 [M + H]<sup>+</sup>.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-Methyl-4-(6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)benzamide (<b>42i</b>)</h3><div class="NLM_p last">Yield = 69%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (s, 1H), 8.58 (d, <i>J</i> = 4.5 Hz, 1H), 8.38 (d, <i>J</i> = 9.0 Hz, 1H), 8.14–8.07 (m, 3H), 8.03 (d, <i>J</i> = 8.1 Hz, 2H), 6.23 (d, <i>J</i> = 8.9 Hz, 1H), 3.95–3.84 (m, 2H), 2.83 (s, 3H), 2.47 (s, 1H), 2.09 (d, <i>J</i> = 10.2 Hz, 2H), 1.91–1.76 (m, 1H), 1.65–1.89 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.57, 146.72, 143.39, 140.26, 134.87, 134.70, 131.99, 129.28, 128.36, 127.36, 124.79, 122.93, 117.00, 108.06, 84.52, 67.06, 29.33, 26.78, 25.17, 22.38; LC/MS (ESI, <i>m</i>/<i>z</i>) 381.16 [M + H]<sup>+</sup>.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-(4-(4-Methylpiperazin-1-yl)phenyl)-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42j</b>)</h3><div class="NLM_p last">Yield = 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 1H), 8.21 (s, 1H), 8.01 (s, 1H), 7.81 (s, 2H), 7.07 (s, 2H), 6.12 (s, 1H), 3.89 (s, 2H), 3.40 (s, 1H), 3.22 (s, 4H), 2.47 (s, 4H), 2.24 (s, 3H), 2.05 (s, 2H), 1.78 (s, 1H), 1.61 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.52, 146.50, 144.43, 140.09, 128.35, 124.76, 122.87, 122.38, 116.29, 115.63, 107.67, 84.43, 66.99, 54.94, 47.95, 46.19, 29.36, 25.22, 22.44; LC/MS (ESI, <i>m</i>/<i>z</i>) 422.22 [M + H]<sup>+</sup>.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 3-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-6-nitro-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole (<b>42k</b>)</h3><div class="NLM_p last">Yield = 71%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.79 (s, 1H), 8.28 (s, 1H), 8.05 (s, 1H), 7.93 (s, 2H), 7.47 (s, 2H), 6.18 (s, 1H), 3.89 (s, 2H), 3.53 (s, 2H), 2.36 (s, 8H), 2.17 (s, 4H), 2.07 (s, 2H), 1.79 (s, 1H), 1.63 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 146.62, 144.15, 140.16, 139.53, 130.98, 129.94, 127.47, 124.81, 122.86, 116.66, 107.90, 84.48, 66.98, 62.20, 55.14, 52.97, 46.10, 29.33, 25.19, 22.37; LC/MS (ESI, <i>m</i>/<i>z</i>) 436.24 [M + H]<sup>+</sup>.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-(Tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43a</b>)</h3><div class="NLM_p">To a solution of <b>42a</b> (0.50 g, 2 mmol) in methanol (20 mL) was added 10% Pd/C (0.1 g) at room temperature under an argon protection. Then, the reaction mixture was stirred under a balloon of hydrogen for 20 h. The resulting mixture was filtered and washed with methanol. Evaporation of the filtrate provided the crude product, which was purified by silica gel flash chromatography (eluting with 0–30% EtOAc in heptane) to afford <b>43a</b> as a gray solid (0.35 g, 80%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.74 (s, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 6.61 (s, 1H), 6.53 (d, <i>J</i> = 8.6 Hz, 1H), 5.53 (dd, <i>J</i> = 9.5, 1.9 Hz, 1H), 5.36 (s, 2H), 3.87 (d, <i>J</i> = 11.2 Hz, 1H), 3.69–3.55 (m, 1H), 2.41–2.33 (m, 1H), 2.01 (dd, <i>J</i> = 9.2, 4.0 Hz, 1H), 1.91–1.88 (m, 1H), 1.77–1.65 (m, 1H), 1.59–1.52 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 148.57, 141.93, 133.64, 121.43, 116.87, 113.15, 91.30, 84.49, 66.87, 29.29, 25.37, 22.78; LC/MS (ESI, <i>m</i>/<i>z</i>) 218.13 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>43b</b>–<b>k</b> was prepared following the synthetic procedure of compound <b>42c</b>.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 3-Methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43b</b>)</h3><div class="NLM_p last">Yield = 70%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.30 (d, <i>J</i> = 8.5 Hz, 1H), 6.54 (d, <i>J</i> = 4.9 Hz, 1H), 6.49 (d, <i>J</i> = 8.5 Hz, 1H), 5.50–5.38 (m, 1H), 5.31 (s, 2H), 3.87 (d, <i>J</i> = 11.1 Hz, 1H), 3.72–3.59 (m, 1H), 2.40–2.30 (m, 4H), 1.99 (dd, <i>J</i> = 9.5, 3.5 Hz, 1H), 1.84–1.81 (m, 1H), 1.77–1.66 (m, 1H), 1.57–1.47 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 148.62, 142.83, 141.32, 120.85, 116.43, 112.24, 91.32, 84.27, 66.94, 29.40, 25.40, 22.96, 12.11; LC/MS (ESI, <i>m</i>/<i>z</i>) 232.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43c</b>)</h3><div class="NLM_p last">Yield = 69%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.91 (s, 1H), 7.72–7.66 (m, 1H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 6.74 (s, 2H), 5.70–5.48 (m, 1H), 4.71 (s, 1H), 3.86 (s, 1H), 3.65 (s, 1H), 2.43 (s, 1H), 1.99 (s, 1H), 1.90 (s, 1H), 1.71 (s, 2H), 1.54 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 136.92, 132.52, 132.01, 131.91, 129.29, 129.18, 128.91, 115.41, 114.27, 112.70, 83.84, 67.05, 39.57, 29.51, 25.29, 23.04; LC/MS (ESI, <i>m</i>/<i>z</i>) 298.17 [M + H]<sup>+</sup>.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-(Pyridin-3-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43d</b>)</h3><div class="NLM_p last">Yield = 72%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (d, <i>J</i> = 1.6 Hz, 1H), 8.59 (d, <i>J</i> = 4.7 Hz, 1H), 8.26 (d, <i>J</i> = 7.9 Hz, 1H), 7.71 (s, 1H), 7.51 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 6.68 (s, 1H), 6.66 (d, <i>J</i> = 8.7 Hz, 1H), 5.64 (dd, <i>J</i> = 9.4, 1.9 Hz, 1H), 5.52 (s, 2H), 3.92 (d, <i>J</i> = 11.4 Hz, 1H), 3.80–3.61 (m, 1H), 2.48–2.40 (m, 1H), 2.12–2.02 (m, 1H), 1.98–1.92 (m, 1H), 1.82–1.70 (m, 1H), 1.64–1.55 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 149.09, 148.89, 147.86, 143.57, 140.42, 134.34, 130.01, 124.42, 121.47, 114.23, 114.02, 91.47, 84.65, 66.98, 29.22, 25.32, 22.68; LC/MS (ESI, <i>m</i>/<i>z</i>) 295.16 [M + H]<sup>+</sup>.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 3-(6-Methylpyridin-3-yl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43e</b>)</h3><div class="NLM_p last">Yield = 74%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (d, <i>J</i> = 7.2 Hz, 1H), 8.17 (d, <i>J</i> = 7.9 Hz, 1H), 7.71 (t, <i>J</i> = 7.5 Hz, 1H), 7.36 (t, <i>J</i> = 7.7 Hz, 1H), 6.79–6.58 (m, 2H), 5.77 (s, 2H), 5.64 (d, <i>J</i> = 8.9 Hz, 1H), 3.92 (s, 1H), 3.70 (s, 1H), 2.53 (s, 2H), 2.46 (s, 1H), 2.19–1.79 (m, 2H), 1.74 (s, 1H), 1.58 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.46, 148.81, 147.07, 143.53, 140.61, 134.72, 127.25, 123.69, 121.49, 114.09, 91.54, 84.66, 67.01, 55.38, 29.26, 25.33, 24.26, 22.73; LC/MS (ESI, <i>m</i>/<i>z</i>) 309.17 [M + H]<sup>+</sup>.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 5-(6-Amino-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)-<i>N</i>-methylnicotinamide (<b>43f</b>)</h3><div class="NLM_p last">Yield = 65%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 9.04 (s, 1H), 8.90 (s, 1H), 8.67 (s, 1H), 8.01 (d, <i>J</i> = 8.7 Hz, 1H), 7.17 (s, 1H), 6.96 (d, <i>J</i> = 8.7 Hz, 1H), 5.80 (t, <i>J</i> = 11.3 Hz, 1H), 3.93 (d, <i>J</i> = 11.3 Hz, 1H), 3.79–3.70 (m, 1H), 2.86 (d, <i>J</i> = 4.4 Hz, 3H), 2.44 (s, 1H), 2.06 (dd, <i>J</i> = 24.0, 8.9 Hz, 2H), 1.88–1.74 (m, 1H), 1.62 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.25, 149.40, 147.66, 142.56, 139.96, 133.14, 130.75, 129.43, 122.15, 116.77, 116.06, 97.13, 84.90, 67.06, 29.24, 26.75, 25.42, 25.25, 22.53; LC/MS (ESI, <i>m</i>/<i>z</i>) 352.18 [M + H]<sup>+</sup>.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-(3-Fluorophenyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43g</b>)</h3><div class="NLM_p last">Yield = 76%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (t, <i>J</i> = 9.6 Hz, 1H), 7.70 (t, <i>J</i> = 13.7 Hz, 1H), 7.64 (d, <i>J</i> = 10.4 Hz, 1H), 7.57–7.49 (m, 1H), 7.25–7.17 (m, 1H), 6.67–6.65 (m, 2H), 5.63 (d, <i>J</i> = 9.2 Hz, 1H), 5.50 (s, 2H), 3.91 (d, <i>J</i> = 11.3 Hz, 1H), 3.78–3.64 (m, 1H), 2.49–2.41 (m, 1H), 2.13–2.01 (m, 1H), 1.98–1.95 (m, 1H), 1.80–1.71 (m, 1H), 1.63–1.55 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.66, 160.77, 147.92, 142.49, 140.85, 135.36, 130.18, 122.05, 120.09, 113.88, 113.09, 112.84, 112.23, 90.42, 83.52, 65.87, 28.14, 24.26, 21.61; LC/MS (ESI, <i>m</i>/<i>z</i>) 312.15 [M + H]<sup>+</sup>.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-(6-Amino-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)benzamide (<b>43h</b>)</h3><div class="NLM_p last">Yield = 65%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (s, 1H), 8.13 (s, 1H), 8.04 (d, <i>J</i> = 7.6 Hz, 1H), 7.88 (d, <i>J</i> = 7.7 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.45 (s, 1H), 6.66 (d, <i>J</i> = 10.9 Hz, 2H), 5.63 (d, <i>J</i> = 9.5 Hz, 1H), 5.49 (s, 2H), 3.94–3.91 (m, 1H), 3.74–3.66 (m, 1H), 2.48–2.42 (m, 1H), 2.10–1.94 (m, 2H), 1.81–1.67 (m, 1H), 1.62–1.55 (m, 2H); LC/MS (ESI, <i>m</i>/<i>z</i>) 337.17 [M + H]<sup>+</sup>.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 4-(6-Amino-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-3-yl)-<i>N</i>-methylbenzamide (<b>43i</b>)</h3><div class="NLM_p last">Yield = 69%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (s, 1H), 8.01–7.99 (m, 2H), 7.95 (d, <i>J</i> = 8.0 Hz, 2H), 7.76 (dd, <i>J</i> = 8.7, 3.7 Hz, 1H), 6.67 (d, <i>J</i> = 11.2 Hz, 2H), 5.63 (d, <i>J</i> = 9.4 Hz, 1H), 5.50 (s, 2H), 3.92 (d, <i>J</i> = 11.3 Hz, 1H), 3.74–3.66 (m, 1H), 2.82 (d, <i>J</i> = 3.4 Hz, 2H), 2.44 (dd, <i>J</i> = 17.5, 8.2 Hz, 1H), 2.07–1.94 (m, 2H), 1.79–1.73 (m, 1H), 1.62–1.57 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.80, 148.75, 143.65, 142.25, 136.64, 133.85, 131.99, 129.28, 128.06, 126.78, 121.67, 114.11, 84.62, 67.00, 29.26, 26.75, 25.34, 22.72; LC/MS (ESI, <i>m</i>/<i>z</i>) 351.18 [M + H]<sup>+</sup>.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-(4-(4-Methylpiperazin-1-yl)phenyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43j</b>)</h3><div class="NLM_p last">Yield = 68%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (s, 2H), 7.65 (s, 1H), 7.02 (s, 2H), 6.64 (s, 2H), 5.57 (s, 1H), 5.42 (s, 2H), 3.91 (s, 1H), 3.68 (s, 1H), 3.37 (s, 1H), 3.18 (s, 4H), 2.46 (s, 4H), 2.23 (s, 3H), 2.00 (d, <i>J</i> = 37.4 Hz, 2H), 1.74 (s, 1H), 1.57 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.88, 148.47, 143.52, 143.34, 127.91, 124.65, 121.75, 115.62, 114.21, 113.39, 91.58, 84.57, 66.94, 55.04, 48.26, 46.25, 29.33, 25.40, 22.83; LC/MS (ESI, <i>m</i>/<i>z</i>) 392.25 [M + H]<sup>+</sup>.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazol-6-amine (<b>43k</b>)</h3><div class="NLM_p last">Yield = 70%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88 (d, <i>J</i> = 7.8 Hz, 2H), 7.72 (d, <i>J</i> = 8.7 Hz, 1H), 7.43 (d, <i>J</i> = 7.9 Hz, 2H), 6.69 (s, 1H), 6.66 (d, <i>J</i> = 8.8 Hz, 1H), 5.64 (d, <i>J</i> = 8.0 Hz, 1H), 5.49 (s, 2H), 3.95–3.93 (m, 1H), 3.78–3.68 (m, 1H), 3.53 (s, 2H), 2.51–2.36 (m, 9H), 2.20 (s, 3H), 2.12–2.03 (m, 1H), 2.01–1.95 (m, 1H), 1.83–1.70 (m, 1H), 1.62 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 148.62, 143.56, 143.06, 138.26, 134.49, 132.86, 129.67, 127.00, 121.67, 114.13, 113.75, 84.55, 66.93, 62.34, 55.18, 53.02, 46.17, 29.28, 25.14, 22.75; LC/MS (ESI, <i>m</i>/<i>z</i>) 406.26 [M + H]<sup>+</sup>.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Methyl 3-((4-Chloro-3-(trifluoromethyl)phenyl)amino)-3-oxopropanoate (<b>45</b>)</h3><div class="NLM_p last">Yield = 83%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.65 (s, 1H), 8.16 (d, <i>J</i> = 1.6 Hz, 1H), 7.81 (d, <i>J</i> = 8.7 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 3.67 (s, 3H), 3.52 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.22, 165.23, 138.66, 132.73, 127.38, 124.72, 124.35, 122.04, 118.16, 118.12, 52.54, 43.96; LC/MS (ESI, <i>m</i>/<i>z</i>) 296.03 [M + H]<sup>+</sup>.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 3-((4-Chloro-3-(trifluoromethyl)phenyl)amino)-3-oxopropanoic Acid (<b>46</b>)</h3><div class="NLM_p last">Yield = 74%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.29 (s, 1H), 8.23 (d, <i>J</i> = 1.8 Hz, 1H), 7.84 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 3.29 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.01, 167.36, 139.11, 132.50, 127.01, 124.27, 124.17, 124.05, 122.10, 117.95, 45.52; LC/MS (ESI, <i>m</i>/<i>z</i>) 297.04 [M + H]<sup>+</sup>.</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Biochemical Kinase Assay</h3><div class="NLM_p">The inhibitory activities of <b>24</b> against c-KIT and c-KIT T670I were determined by the Z’-LYTE assay. The optimized enzyme concentrations were chosen as follows: c-KIT 20 ng/μL, c-KIT T670I 15 ng/μL. In all cases, 2.5 μL samples of kinase were incubated with <b>24</b> for 60 min at room temperature in reaction buffer followed by addition of 2.5 μL of ATP/substrate mixture. The ATP concentration was chosen as follows: 50 μM ATP for c-KIT or c-KIT T670I. The assay was conducted for 1 h at 37 °C before addition of 5 μL of ADP-Glo reagent and incubation for 40 min at room temperature. Ten microliters of kinase detection reagent was added and incubated for 30 min at room temperature before the luminescence signal was read with an envision PerkinElmer plate reader (Envision, PE), and then the dose–response curve was fitted using Prism 7.0 (GraphPad Software Inc., San Diego, CA). The biochemical tests of other targets were provided by Invitrogen (Carlsbad, CA).</div><div class="NLM_p last">Imatinib and ponatinib were purchased from MedChem Express (Shanghai, China).</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Cell Lines, Antibodies, and Chemicals</h3><div class="NLM_p">The human GIST-T1 cell line was purchased from Cosmo Bio Co., Ltd. (Tokyo, Japan). GIST-882 and GIST-48B cell lines were kindly provided by the group of Professor Jonathan A. Fletcher, Brigham and Women’s Hospital in Boston. GIST-T1-T670I and TEL-isogenic BaF3 cell lines were established in our lab. GIST-5R cell line was kindly provided by Prof. Brian Rubin, Department of Molecular Genetics, Lerner Research Institute, and Department of Anatomic Pathology and Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195. GIST-T1, GIST-T1-T670I, and GIST-5R cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Corning) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. GIST-882 and GIST-8B cell lines were maintained in improved minimum essential medium (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin. Isogenic BaF3 cells lines were cultured in Roswell Park Memorial Institute 1640 media (Corning) with 10% fetal bovine serum (FBS) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. All cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>.</div><div class="NLM_p last">The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): AKT (pan) (C67E7) rabbit mAb (no. 4691), phospho-AKT (Thr308) (244F9) rabbit mAb (no. 4056), phospho-AKT (Ser473) (D9E) XP rabbit mAb (no. 4060), GAPDH (D16H11) XP rabbit mAb, PARP (46D11) rabbit mAb (no. 9532), caspase-3 (8G10) rabbit mAb (no. 9665), phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (197G2) rabbit mAb (no. 4377), p44/42 MAPK (ERK1/2) (137F5) rabbit mAb (no. 4695), c-KIT (Ab81) mouse mAb (no. 3308), phospho-c-KIT (Tyr703) (D12E12) rabbit mAb (no. 3073), phospho-c-Kit (Tyr719) antibody (no. 3391), phospho-anti-c-Kit (p-Y823) rabbit mAb (no. 77522), phosphoSTAT3 (Tyr705) (D3A7) XP rabbit mAb (Biotinylated) (no. 4093), STAT3 (D3Z2G) rabbit mAb no. 12640, phospho-S6 ribosomal protein (Ser235/236) antibody (no. 2211), and S6 ribosomal protein (5G10) rabbit mAb (no. 2217).</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Generation of GIST-T1-T670I Cell Line Using CRISPR/Cas9 System</h3><div class="NLM_p last">SgRNA targeting the genomic region surrounding T670 site of KIT gene was designed and synthesized. Annealed sgRNA oligos were inserted into pSpCas9(BB)-2A-Puro (PX459) V2.0 vector (Addgene, Cambridge, MA) and transfected into GIST-T1 cells together with a 90 nt oligo containing T670I mutation as a homology-directed repair template by Lipofectamine 3000 (Invitrogen, Carlsbad, CA). Antibiotic selection with puromycin was performed 2 days after transfection, and then cells were diluted and cultured in 96-well plates with only one cell per well for 3 weeks. Correctly edited T670I knock-in cell clones were then confirmed by Sanger sequencing at the targeted genomic region.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> General Procedure for Antiproliferation Assays</h3><div class="NLM_p last">For the nonadherent cells, cells with a density of 1.5–5 × 10<sup>4</sup> cells/mL were mixed with various concentrations of compounds; then, 100 μL of suspension was added to each well and then incubated at 37 °C with 5% CO<sub>2</sub> for 72 h. For the adherent cells, a cell with a density of 1.5–5 × 10<sup>4</sup> cells/mL were added to a 96-well plate and incubated at 37 °C with 5% CO<sub>2</sub> overnight. The next day, the supernatants were changed with fresh medium containing various concentrations of compounds and then incubated for 72 h. Cell viability was determined using Cell Counting Kit-8 (MedChem Express, China) according to the instruction manual. The absorbance was measured in a microplate reader (iMARK, Bio-Rad) at 450 nm. Data were normalized to control group (DMSO). GI<sub>50</sub> values were calculated using Prism 7.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> c-KIT Protein Purification</h3><div class="NLM_p last">The sequences encoding c-KIT wt and c-KIT T670I residues 544–935 with a Histag were cloned into baculovirus expression vector pFASTHTA. The proteins were expressed by infecting SF9 cells with high titer viral stocks for 48 h. Cells were harvested and lysed in 25 mM Tris pH 7.4, 250 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride. The supernatant was loaded to Ni-NTA column (QIAGEN, 1018244). Then, the proteins were step-eluted with the same buffer with 250 mM imidazole. The eluted proteins were loaded on a Superdex-200 column equilibrated in 25 mM Tris (pH 7.4), 250 mM NaCl, 1 mM dithiothreitol, and 1 mM ethylenediaminetetraacetic acid. Peak fractions were concentrated to 2 mg/mL and flash-frozen.</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Signaling Pathway Study</h3><div class="NLM_p last">GIST-T1, GIST-T1-T670I, and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. The serially diluted compound <b>24</b> was added to cells for 1 h. The cells were collected and lysed. The cell lysates were analyzed by Western blotting. Western blotting was performed by standard methods, as previously described.</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Apoptosis Effect Examination</h3><div class="NLM_p last">GIST-T1, GIST-T1-T670I, and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. The serially diluted compound <b>24</b> was added to cells for 24 h. Then, apoptosis of GIST-T1, GIST-T1-T670I, and GIST-5R cells was detected by Western blot using PARP and GAPDH antibodies (Cell Signaling Technology).</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Rodent Pharmacokinetics</h3><div class="NLM_p last">The study protocol was approved by the animal ethics committee of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). The male Sprague-Dawley rats (190–210 g) were provided by the laboratory animal center of Anhui Medical University (Hefei, China). The animals were housed in an air-conditioned animal room at a temperature of 23 ± 2 °C and a relative humidity of 50 ± 10% and allowed free access to tap water and lab. The rats were acclimatized to the facilities for 1 week and then fasted for 12 h with free access to water prior to the experiment. The rats were randomly and equally divided into two groups for the pharmacokinetic study of the compound. One group was injected with i.v. formulation at a dose of 1 mg/kg. The other group was treated by oral administration of p.o. formulation at doses of 10 mg/kg. The i.v. formulation for rats consisted of 5 mg of the compound dissolved in 0.5 mL of dimethyl sulfoxide and 4.5 mL of 5% glucose water. The p.o. formulation for rats was made with 50 mg of the compound dissolved in 0.5 mL of dimethyl sulfoxide and 4.5 mL of 5% glucose water. About 300 μL of blood samples were collected into heparinized tubes at 2, 5, 15, 30, 60, 120, 240, 360, 540, and 720 min after intravenous injection of compound <b>24</b> and at 5, 15, 30, 60, 90, 120, 240, 360, 540, and 720 min after oral administration of compound <b>24</b>. Hundred microliters of plasma was harvested by centrifuging the blood sample at 4 °C and 5000 rpm for 3 min, and then stored at −80 °C until analysis. An aliquot of 100 μL of each plasma sample was mixed with 20 μL of internal standard working solution (200 ng/mL caffeine). Methanol (400 μL) was then added for precipitation. After vortexing for 5 min and centrifuging at 14 000 rpm for 10 min, 5 μL of the supernatant was injected for LC–tandem mass spectrometry analysis. The pharmacokinetic parameters were analyzed through a noncompartment model using WinNonlin 6.1 software (Pharsight Corporation, Mountain View). The oral bioavailability (<i>F</i>) is calculated according to the following equation: <i>F</i> = AUC<sub>0–∞</sub> (oral)/AUC<sub>0–∞</sub> (i.v.) × dose (i.v.)/dose (oral) × 100%.</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> GIST-5R Xenograft Model</h3><div class="NLM_p last">Five-week old female nu/nu mice were purchased from the Nanjing Biomedical Research Institute of Nanjing University (Nanjing, China). All animals were maintained in the Animal Center of Hefei Institutes of Physical Science, Chinese Academy of Sciences according to the Guide for the Care and Use of Laboratory Animals [National Research Council (U.S.) Committee]. All experimental protocols were approved by the Hefei Institutes of Physical Science ethics committee, Chinese Academy of Sciences (approval no. HFCASDWLL20160512). All efforts were made to minimize animal suffering. To obtain orthotopic xenograft of human mammary tumor in the mice, cells were harvested during exponential growth. One million GIST-5R cells in PBS were suspended in a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily p.o. administration was initiated when GIST-5R tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of four mice each for efficacy studies. Compound <b>24</b> was delivered in a HKI suspension (0.5% methocellulose/0.4% Tween80 in ddH<sub>2</sub>O) by p.o. (QD). A range of doses of <b>24</b> or its vehicle was administered, as indicated in the <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> legend. Body weight and tumor growth were measured daily after <b>24</b> treatment. Tumor volumes were calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Molecular Modeling</h3><div class="NLM_p last">All calculations were performed using the Schrödinger Suite. The DFG-out c-KIT complex (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) was used for docking studies. The crystal structure was prepared using the Protein Preparation Wizard and the T670I mutant was modeled in situ within Maestro. The ligand structures were built in Maestro and prepared for docking using LigPrep (LigPrep 3.4, Schrödinger, LLC, New York, NY) and further docked into the receptor by the IFD protocol (Induced Fit Docking protocol, Schrödinger, LLC, New York, NY).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00176" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00176" class="ext-link">10.1021/acs.jmedchem.9b00176</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Listing the DiscoverX’s KINOMEscan selectivity profiling data of <b>24</b> (Supplementary Table 1); listing the pharmacodynamic evaluation of <b>24</b> in the GIST-5R xenograft mouse model (Supplementary Figure 1) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docking poses for <b>6</b>, <b>7</b>, and <b>24</b> with c-KIT T670I and docking pose for <b>24</b> with c-KIT wt (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_003.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf">jm9b00176_si_001.pdf (781.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_002.csv">jm9b00176_si_002.csv (4.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_003.zip">jm9b00176_si_003.zip (281.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00176" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Institutes
of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#90e1e3fcf9e5a9a7d0f8fdf6fcbef1f3bef3fe"><span class="__cf_email__" data-cfemail="87f6f4ebeef2beb0c7efeae1eba9e6e4a9e4e9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#85efecebe2e9ecf0c5ede8e3e9abe4e6abe6eb"><span class="__cf_email__" data-cfemail="f3999a9d949f9a86b39b9e959fdd9290dd909d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuesong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junjie Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Ge</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingwang Liu</span> - <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenquan Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zongru Jiang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes
of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precedo
Pharmaceuticals Inc., Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingfeng Bai</span> - <span class="hlFld-Affiliation affiliation">Molecular
Imaging Laboratory, Department of Radiology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.L., B.W., C.C., and Z.Q. contribute equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. X.L., B.W., C.C., and A.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5842-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32733" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32733" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (Grants 81603123, 81803366, 21708044, 81673469, 81773777, and 81872748), the “Personalized Medicines-Molecular Signature-Based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDA12020224), the China Postdoctoral Science Foundation (Grants 2018T110634 and 2018M630720), the Natural Science Foundation of Anhui Province (Grants 1808085MH268), the Major Science and Technology Program of Anhui Province (Grant 18030801116), the Key Research and Development Program of Anhui Province (Grant 1704a0802140), the Key Technology Research and Development Program of Hefei (Grant ZR201711290017), and the Frontier Science Key Research Program of CAS (Grant QYZDB-SSW-SLH037). We are also grateful for the National Program for Support of Top-Notch Young Professionals for J.L. and the support of Hefei leading talent for F.Z.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">GISTs</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">JM</td><td class="NLM_def"><p class="first last">juxtamembrane</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Stromal Tumor</span>. <i>J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2078-6891.2012.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.3978%2Fj.issn.2078-6891.2012.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22943011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSnur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=189-208&author=X.+Zhaoauthor=C.+Yue&title=Gastrointestinal+Stromal+Tumor&doi=10.3978%2Fj.issn.2078-6891.2012.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Zhao, Xiaohui; Yue, Changjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gastrointestinal Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-208</span>CODEN:
                <span class="NLM_cas:coden">JGOOBI</span>;
        ISSN:<span class="NLM_cas:issn">2078-6891</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its unique biol. behavior, clinicopathol. features, mol. mechanisms, and treatment implications.  GIST is the most common mesenchymal neoplasm in the gastrointestinal tract and has emerged from a poorly understood and treatment resistant neoplasm to a well-defined tumor entity since the discovery of particular mol. abnormalities, KIT and PDGFRA gene mutations.  The understanding of GIST biol. at the mol. level promised the development of novel treatment modalities.  Diagnosis of GIST depends on the integrity of histol., immunohistochem. and mol. anal.  The risk assessment of the tumor behavior relies heavily on pathol. evaluation and significantly impacts clin. management.  In this review, historic review, epidemiol., pathogenesis and genetics, diagnosis, role of mol. anal., prognostic factor and treatment strategies have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZLlQkdrwIHbVg90H21EOLACvtfcHk0lhMw8JrerwU6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSnur7P&md5=5c68011b08fc986273fd417c1bee554b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2078-6891.2012.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2078-6891.2012.031%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DC.%26atitle%3DGastrointestinal%2520Stromal%2520Tumor%26jtitle%3DJ.%2520Gastrointest.%2520Oncol.%26date%3D2012%26volume%3D3%26spage%3D189%26epage%3D208%26doi%3D10.3978%2Fj.issn.2078-6891.2012.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-Function Mutations of c-KIT in Human Gastrointestinal Stromal Tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-Function+Mutations+of+c-KIT+in+Human+Gastrointestinal+Stromal+Tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lixZXv0IWBrQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-Function%2520Mutations%2520of%2520c-KIT%2520in%2520Human%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindblom, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remotti, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldenborg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meis-Kindblom, J. M.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajal</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1002/jemt.1060180315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1002%2Fjemt.1060180315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=9588894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1998&pages=1259-1269&author=L.+G.+Kindblomauthor=H.+E.+Remottiauthor=F.+Aldenborgauthor=J.+M.+Meis-Kindblom&title=Gastrointestinal+Pacemaker+Cell+Tumor+%28GIPACT%29%3A+Gastrointestinal+Stromal+Tumors+Show+Phenotypic+Characteristics+of+the+Interstitial+Cells+of+Cajal&doi=10.1002%2Fjemt.1060180315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span></div><div class="casAuthors">Kindblom L G; Remotti H E; Aldenborg F; Meis-Kindblom J M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1259-69</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The interstitial cells of Cajal (ICC) form a complex cell network within the gastrointestinal tract wall where they function as a pacemaker system.  Expression of the kit proto-oncogene is essential for the development of this system.  The aim of our study was to examine the hypothesis that gastrointestinal stromal tumors differentiate toward cells with an ICC phenotype.  Ultrastructurally, 58 stromal tumors were characterized and found to share many features with ICC.  Seventy-eight stromal tumors were immunophenotyped, particularly with regard to the kit receptor.  All 78 tumors revealed strong, homogeneous immunoreactivity for the kit receptor as did ICC of adjacent and control gastrointestinal walls.  Focal hyperplasia and hypertrophy of kit receptor positive cells were also observed in the gastrointestinal wall adjacent to the tumors.  CD34 immunoreactivity observed in interstitial cells surrounding Auerbach's ganglia suggests that a subpopulation of ICC is CD34 positive and may explain why 56 of 78 stromal tumors were CD34 positive.  Thirty control tumors, including gastrointestinal leiomyomas and leiomyosarcomas, were all negative for the kit receptor.  We conclude that gastrointestinal stromal tumors show striking morphological and immunophenotypic similarities with ICC and that they may originate from stem cells that differentiate toward a pacemaker cell phenotype.  We propose that the noncommittal name "gastrointestinal stromal tumor" be replaced by gastrointestinal pacemaker cell tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo1_gLlQJ49LesJRIHUP1ofW6udTcc2eYIsFsqcqdOBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D&md5=fb5342253954593446205c2ea24b21e3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjemt.1060180315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjemt.1060180315%26sid%3Dliteratum%253Aachs%26aulast%3DKindblom%26aufirst%3DL.%2BG.%26aulast%3DRemotti%26aufirst%3DH.%2BE.%26aulast%3DAldenborg%26aufirst%3DF.%26aulast%3DMeis-Kindblom%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520Pacemaker%2520Cell%2520Tumor%2520%2528GIPACT%2529%253A%2520Gastrointestinal%2520Stromal%2520Tumors%2520Show%2520Phenotypic%2520Characteristics%2520of%2520the%2520Interstitial%2520Cells%2520of%2520Cajal%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D152%26spage%3D1259%26epage%3D1269%26doi%3D10.1002%2Fjemt.1060180315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennartsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span> <span> </span><span class="NLM_article-title">Stem Cell Factor Receptor/C-Kit: From Basic Science to Clinical Implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1619</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+R%C3%B6nnstrand&title=Stem+Cell+Factor+Receptor%2FC-Kit%3A+From+Basic+Science+to+Clinical+Implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0lgmRFGq0_n8Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DStem%2520Cell%2520Factor%2520Receptor%252FC-Kit%253A%2520From%2520Basic%2520Science%2520to%2520Clinical%2520Implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, T.</span></span> <span> </span><span class="NLM_article-title">Enrichment and Characterization of Murine Hematopoietic Stem Cells That Express C-Kit Molecule</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1007/BF01703451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1007%2FBF01703451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1991&pages=1706-1712&author=S.+Okadaauthor=H.+Nakauchiauthor=K.+Nagayoshiauthor=S.+Nishikawaauthor=S.+Nishikawaauthor=Y.+Miuraauthor=T.+Suda&title=Enrichment+and+Characterization+of+Murine+Hematopoietic+Stem+Cells+That+Express+C-Kit+Molecule&doi=10.1007%2FBF01703451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2FBF01703451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01703451%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DNakauchi%26aufirst%3DH.%26aulast%3DNagayoshi%26aufirst%3DK.%26aulast%3DNishikawa%26aufirst%3DS.%26aulast%3DNishikawa%26aufirst%3DS.%26aulast%3DMiura%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DT.%26atitle%3DEnrichment%2520and%2520Characterization%2520of%2520Murine%2520Hematopoietic%2520Stem%2520Cells%2520That%2520Express%2520C-Kit%2520Molecule%26jtitle%3DBlood%26date%3D1991%26volume%3D78%26spage%3D1706%26epage%3D1712%26doi%3D10.1007%2FBF01703451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oosterhuis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looijenga, L. H. J.</span></span> <span> </span><span class="NLM_article-title">Testicular Germ-Cell Tumors in a Broader Perspective</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/nrc1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnrc1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=15738984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=210-222&author=J.+W.+Oosterhuisauthor=L.+H.+J.+Looijenga&title=Testicular+Germ-Cell+Tumors+in+a+Broader+Perspective&doi=10.1038%2Fnrc1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular germ-cell tumors in a broader perspective</span></div><div class="casAuthors">Oosterhuis, J. Wolter; Looijenga, Leendert H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-222</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The germ-cell tumors are a fascinating group of neoplasms because of their unusual biol. and the spectacular therapeutic results that have been obtained in these tumors.  Traditionally, this group of neoplasms is presented in an organ-oriented approach.  However, recent clin. and exptl. data convincingly demonstrate that these neoplasms are one disease with sep. entities that can manifest themselves in different anatomical sites.  We propose five entities, in which the developmental potential is detd. by the maturation stage and imprinting status of the originating germ cell.  Recent progress begins to explain the apparent unpredictable development of germ-cell tumors and offers a basis for understanding their exquisite sensitivity to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNiWrq2TenmbVg90H21EOLACvtfcHk0liYJuvzUM1BIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7Y%253D&md5=9d7ab492c16016d6ee364897a8cb08d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1568%26sid%3Dliteratum%253Aachs%26aulast%3DOosterhuis%26aufirst%3DJ.%2BW.%26aulast%3DLooijenga%26aufirst%3DL.%2BH.%2BJ.%26atitle%3DTesticular%2520Germ-Cell%2520Tumors%2520in%2520a%2520Broader%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D210%26epage%3D222%26doi%3D10.1038%2Fnrc1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriss, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span> <span> </span><span class="NLM_article-title">Signaling of C-Kit in Dendritic Cells Influences Adaptive Immunity</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1183</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05122.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1111%2Fj.1749-6632.2009.05122.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1183&publication_year=2010&pages=104-122&author=P.+Rayauthor=N.+Krishnamoorthyauthor=T.+B.+Orissauthor=A.+Ray&title=Signaling+of+C-Kit+in+Dendritic+Cells+Influences+Adaptive+Immunity&doi=10.1111%2Fj.1749-6632.2009.05122.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05122.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05122.x%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DP.%26aulast%3DKrishnamoorthy%26aufirst%3DN.%26aulast%3DOriss%26aufirst%3DT.%2BB.%26aulast%3DRay%26aufirst%3DA.%26atitle%3DSignaling%2520of%2520C-Kit%2520in%2520Dendritic%2520Cells%2520Influences%2520Adaptive%2520Immunity%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1183%26spage%3D104%26epage%3D122%26doi%3D10.1111%2Fj.1749-6632.2009.05122.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redegeld, F. A.</span></span> In  <i>Encyclopedia of Immunotoxicology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohr, H.-W.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2005</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1-5&author=F.+A.+Redegeldauthor=H.-W.+Vohr&title=Encyclopedia+of+Immunotoxicology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRedegeld%26aufirst%3DF.%2BA.%26btitle%3DEncyclopedia%2520of%2520Immunotoxicology%26aulast%3DVohr%26aufirst%3DH.-W.%26pub%3DSpringer%26date%3D2005%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussouar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazelin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauszig-Delamasure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldschneider, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlen, P.</span></span> <span> </span><span class="NLM_article-title">The Proto-Oncogene C-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.08.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.molcel.2018.08.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=413-425&author=H.+Wangauthor=A.+Boussouarauthor=L.+Mazelinauthor=S.+Tauszig-Delamasureauthor=Y.+Sunauthor=D.+Goldschneiderauthor=A.+Paradisiauthor=P.+Mehlen&title=The+Proto-Oncogene+C-Kit+Inhibits+Tumor+Growth+by+Behaving+as+a+Dependence+Receptor&doi=10.1016%2Fj.molcel.2018.08.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.08.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.08.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBoussouar%26aufirst%3DA.%26aulast%3DMazelin%26aufirst%3DL.%26aulast%3DTauszig-Delamasure%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGoldschneider%26aufirst%3DD.%26aulast%3DParadisi%26aufirst%3DA.%26aulast%3DMehlen%26aufirst%3DP.%26atitle%3DThe%2520Proto-Oncogene%2520C-Kit%2520Inhibits%2520Tumor%2520Growth%2520by%2520Behaving%2520as%2520a%2520Dependence%2520Receptor%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D72%26spage%3D413%26epage%3D425%26doi%3D10.1016%2Fj.molcel.2018.08.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbaspour
Babaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huri, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, F.</span></span> <span> </span><span class="NLM_article-title">Receptor Tyrosine Kinase (C-Kit) Inhibitors: A Potential Therapeutic Target in Cancer Cells</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2459</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour%0ABabaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Z.+Huriauthor=F.+Ahmadipour&title=Receptor+Tyrosine+Kinase+%28C-Kit%29+Inhibitors%3A+A+Potential+Therapeutic+Target+in+Cancer+Cells&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2ea9SgpXLA5Xrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DHuri%26aufirst%3DH.%2BZ.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520Tyrosine%2520Kinase%2520%2528C-Kit%2529%2520Inhibitors%253A%2520A%2520Potential%2520Therapeutic%2520Target%2520in%2520Cancer%2520Cells%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarlomo-Rikala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tervahartiala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Effect of the Tyrosine Kinase Inhibitor Sti571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+Tyrosine+Kinase+Inhibitor+Sti571+in+a+Patient+with+a+Metastatic+Gastrointestinal+Stromal+Tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2ea9SgpXLA5Xrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Sti571%2520in%2520a%2520Patient%2520with%2520a%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogendoorn, P. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Glabbeke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertulli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I.</span></span> <span> </span><span class="NLM_article-title">Progression-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+W.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-Free+Survival+in+Gastrointestinal+Stromal+Tumours+with+High-Dose+Imatinib%3A+Randomised+Trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%2BW.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-Free%2520Survival%2520in%2520Gastrointestinal%2520Stromal%2520Tumours%2520with%2520High-Dose%2520Imatinib%253A%2520Randomised%2520Trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs through Secondary Gene Mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singer&title=Acquired+Resistance+to+Imatinib+in+Gastrointestinal+Stromal+Tumor+Occurs+through+Secondary+Gene+Mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0ljDzR5NwnOAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26atitle%3DAcquired%2520Resistance%2520to%2520Imatinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Occurs%2520through%2520Secondary%2520Gene%2520Mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumors and Activity of the Pkc412 Inhibitor against Imatinib-Resistant Mutants</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychter&title=Mechanisms+of+Resistance+to+Imatinib+Mesylate+in+Gastrointestinal+Stromal+Tumors+and+Activity+of+the+Pkc412+Inhibitor+against+Imatinib-Resistant+Mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Imatinib%2520Mesylate%2520in%2520Gastrointestinal%2520Stromal%2520Tumors%2520and%2520Activity%2520of%2520the%2520Pkc412%2520Inhibitor%2520against%2520Imatinib-Resistant%2520Mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandau, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4764</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+V.+von+Mehrenauthor=C.+D.+M.+Fletcherauthor=K.+Sandau&title=Molecular+Correlates+of+Imatinib+Resistance+in+Gastrointestinal+Stromal+Tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0libcyuJTLMr4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%2BV.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSandau%26aufirst%3DK.%26atitle%3DMolecular%2520Correlates%2520of%2520Imatinib%2520Resistance%2520in%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span> <span> </span><span class="NLM_article-title">Kit Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+Dinittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacques&title=Kit+Kinase+Mutants+Show+Unique+Mechanisms+of+Drug+Resistance+to+Imatinib+and+Sunitinib+in+Gastrointestinal+Stromal+Tumor+Patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0libcyuJTLMr4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26atitle%3DKit%2520Kinase%2520Mutants%2520Show%2520Unique%2520Mechanisms%2520of%2520Drug%2520Resistance%2520to%2520Imatinib%2520and%2520Sunitinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manola, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Regorafenib in Patients with Metastatic and/or Unresectable Gi Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2407</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.39.9394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1200%2FJCO.2011.39.9394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22614970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2401-2407&author=S.+Georgeauthor=Q.+Wangauthor=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=M.+Zhuauthor=J.+E.+Butrynskiauthor=J.+A.+Morganauthor=A.+J.+Wagnerauthor=E.+Choyauthor=W.+D.+Tapauthor=J.+T.+Yapauthor=A.+D.+Van+den+Abbeeleauthor=J.+B.+Manolaauthor=S.+M.+Solomonauthor=J.+A.+Fletcherauthor=M.+von+Mehrenauthor=G.+D.+Demetri&title=Efficacy+and+Safety+of+Regorafenib+in+Patients+with+Metastatic+and%2For+Unresectable+Gi+Stromal+Tumor+after+Failure+of+Imatinib+and+Sunitinib%3A+A+Multicenter+Phase+II+Trial&doi=10.1200%2FJCO.2011.39.9394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial</span></div><div class="casAuthors">George, Suzanne; Wang, Qian; Heinrich, Michael C.; Corless, Christopher L.; Zhu, Meijun; Butrynski, James E.; Morgan, Jeffrey A.; Wagner, Andrew J.; Choy, Edwin; Tap, William D.; Yap, Jeffrey T.; Van den Abbeele, Annick D.; Manola, Judith B.; Solomon, Sarah M.; Fletcher, Jonathan A.; von Mehren, Margaret; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2401-2407</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib.  Regorafenib is a structurally unique inhibitor of multiple cancer-assocd. kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclin. and early-phase trials.  Because KIT and PDGFR-α remain drivers of GIST after resistance to imatinib and sunitinib, we performed a multicenter single-stage phase II trial of regorafenib in patients with advanced GIST after failure of at least imatinib and sunitinib.  Patients and Methods: Patients received regorafenib orally, 160 mg daily, on days 1 to 21 of a 28-day cycle.  Disease assessment was performed every two cycles per RECIST 1.1.  Primary end point was clin. benefit rate (CBR), defined as objective responses (ie, complete or partial response [PR] as well as stable disease [SD] ≥ 16 wk).  Serial tumor biopsies were obtained from consenting patients whenever possible.  Results From Feb. to Dec. 2010, 34 patients were enrolled at four US centers.  As of July 28, 2011, 33 patients had received at least two cycles of regorafenib (range, two to 17 cycles).  CBR was 79% (95% CI, 61% to 91%).  Four patients achieved PR, and 22 exhibited SD ≥ 16 wk.  Median progression-free survival was 10.0 mo.  The most common grade 3 toxicities were hypertension and hand-foot-skin reaction.  Conclusion: Regorafenib has significant activity in patients with advanced GIST after failure of both imatinib and sunitinib.  A phase III trial of regorafenib vs. placebo is ongoing to define more fully the safety and efficacy of regorafenib in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RtWuSuSFcbVg90H21EOLACvtfcHk0ljonQlhtV5now"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM&md5=54875f152708a1020a429f24cf398b30</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.39.9394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.39.9394%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DYap%26aufirst%3DJ.%2BT.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DManola%26aufirst%3DJ.%2BB.%26aulast%3DSolomon%26aufirst%3DS.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Regorafenib%2520in%2520Patients%2520with%2520Metastatic%2520and%252For%2520Unresectable%2520Gi%2520Stromal%2520Tumor%2520after%2520Failure%2520of%2520Imatinib%2520and%2520Sunitinib%253A%2520A%2520Multicenter%2520Phase%2520II%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2401%26epage%3D2407%26doi%3D10.1200%2FJCO.2011.39.9394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib Inhibits Polyclonal Drug-Resistant Kit Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (Gist) Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_fpage">5745</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=5745&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+Inhibits+Polyclonal+Drug-Resistant+Kit+Oncoproteins+and+Shows+Therapeutic+Potential+in+Heavily+Pretreated+Gastrointestinal+Stromal+Tumor+%28Gist%29+Patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0ljGxB1qjCOoWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520Inhibits%2520Polyclonal%2520Drug-Resistant%2520Kit%2520Oncoproteins%2520and%2520Shows%2520Therapeutic%2520Potential%2520in%2520Heavily%2520Pretreated%2520Gastrointestinal%2520Stromal%2520Tumor%2520%2528Gist%2529%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26spage%3D5745%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Repurposing Cabozantinib to Gists: Overcoming Multiple Imatinib-Resistant Ckit Mutations Including Gatekeeper and Activation Loop Mutants in Gists Preclinical Models</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.canlet.2019.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=30684595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1KntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2019&pages=105-114&author=T.+Luauthor=C.+Chenauthor=A.+Wangauthor=Z.+Jiangauthor=Z.+Qiauthor=Z.+Huauthor=C.+Huauthor=F.+Liuauthor=W.+Wangauthor=H.+Wuauthor=B.+Wangauthor=L.+Wangauthor=S.+Qiauthor=J.+Wuauthor=W.+Wangauthor=J.+Tangauthor=H.+Yanauthor=M.+Baiauthor=Q.+Liuauthor=J.+Liu&title=Repurposing+Cabozantinib+to+Gists%3A+Overcoming+Multiple+Imatinib-Resistant+Ckit+Mutations+Including+Gatekeeper+and+Activation+Loop+Mutants+in+Gists+Preclinical+Models&doi=10.1016%2Fj.canlet.2019.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models</span></div><div class="casAuthors">Lu, Tingting; Chen, Cheng; Wang, Aoli; Jiang, Zongru; Qi, Ziping; Hu, Zhenquan; Hu, Chen; Liu, Feiyang; Wang, Wenliang; Wu, Hong; Wang, Beilei; Wang, Li; Qi, Shuang; Wu, Jiaxin; Wang, Wenchao; Tang, Jun; Yan, Hezhong; Bai, Mingfeng; Liu, Qingsong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105-114</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Despite of the great success of imatinib as the first-line treatment for GISTs, the majority of patients will develop drug-acquired resistance due to secondary mutations in the cKIT kinase.  Sunitinib and regorafenib have been approved as the second and third line therapies to overcome some of these drug-resistance mutations; however, their limited clin. response, toxicity and resistance of the activation loop mutants still makes new therapies bearing different cKIT mutants activity spectrum profile highly demanded.  Through a drug repositioning approach, we found that cabozantinib exhibited higher potency than imatinib against primary gain-of-function mutations of cKIT.  Moreover, cabozantinib was able to overcome cKIT gatekeeper T670I mutation and the activation loop mutations that are resistant to imatinib or sunitinib.  Cabozantinib demonstrated good efficacy in vitro and in vivo in the cKIT mutant-driven preclin. models of GISTs while displaying a long-lasting effect after treatment withdrawal.  Furthermore, it also exhibited dose-dependent anti-proliferative efficacy in the GIST patient derived primary cells.  Considering clin. safety and PK profile of cabozantinib, this report provides the basis for the future clin. applications of cabozantinib as an alternative anti-GISTs therapy in precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCgeJxg7EnwrVg90H21EOLACvtfcHk0ljrUtNyQpBB3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1KntL8%253D&md5=60675118394473184bf297320107e6a8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRepurposing%2520Cabozantinib%2520to%2520Gists%253A%2520Overcoming%2520Multiple%2520Imatinib-Resistant%2520Ckit%2520Mutations%2520Including%2520Gatekeeper%2520and%2520Activation%2520Loop%2520Mutants%2520in%2520Gists%2520Preclinical%2520Models%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D447%26spage%3D105%26epage%3D114%26doi%3D10.1016%2Fj.canlet.2019.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunnarsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfanzelter, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, S. M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Safety and Efficacy of Axitinib in the Treatment of Advanced Renal Cell Carcinoma</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S74202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.2147%2FCMAR.S74202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25709499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVShur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=65-73&author=O.+Gunnarssonauthor=N.+R.+Pfanzelterauthor=R.+B.+Cohenauthor=S.+M.+Keefe&title=Evaluating+the+Safety+and+Efficacy+of+Axitinib+in+the+Treatment+of+Advanced+Renal+Cell+Carcinoma&doi=10.2147%2FCMAR.S74202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma</span></div><div class="casAuthors">Gunnarsson, Orvar; Pfanzelter, Nicklas R.; Cohen, Roger B.; Keefe, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit.  Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in Phase II trials.  The trial of comparative effectivess of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS) was an international randomized Phase III study designed for registration purposes, compared axitinib to sunitinib.  This trial randomized 723 patients with metastatic kidney cancer to axitinib or sunitinib in the second-line setting and demonstrated a median progression-free survival of 6.7 mo for axitinib vs. 4.7 mo for sorafenib (P<0.0001).  Clin. benefit was detected regardless of prior therapy, but no overall survival benefit has been obsd.  Axitinib is well tolerated without a significant effect on quality of life.  The most common grade 3 toxicities are hypertension (16%), diarrhea (11%), and fatigue (11%), with other notable side effects being anorexia, nausea, hand-foot syndrome, and rash.  Patients who developed diastolic blood pressure >90 mmHg were noted to have significantly longer median overall survival and overall response rates when compared to normotensive patients.  Therefore, the manufacturer recommends escalating the twice-daily dose to 7 mg and 10 mg, as tolerated, if there is no significant increase in blood pressure on treatment.  Currently, axitinib is approved for use in the second-line setting for patients with metastatic renal cell carcinoma.  Research is ongoing in other disease settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVP3EHxMBIWLVg90H21EOLACvtfcHk0ljrUtNyQpBB3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVShur%252FM&md5=4d9aeb0b16a4eed78dfab565d41a6edd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S74202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S74202%26sid%3Dliteratum%253Aachs%26aulast%3DGunnarsson%26aufirst%3DO.%26aulast%3DPfanzelter%26aufirst%3DN.%2BR.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DKeefe%26aufirst%3DS.%2BM.%26atitle%3DEvaluating%2520the%2520Safety%2520and%2520Efficacy%2520of%2520Axitinib%2520in%2520the%2520Treatment%2520of%2520Advanced%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2015%26volume%3D7%26spage%3D65%26epage%3D73%26doi%3D10.2147%2FCMAR.S74202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0liRSpooLuzqEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790m</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+against+EGFR+T790m&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liRSpooLuzqEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520against%2520EGFR%2520T790m%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Inhibitors That Bind to Inactive Kinase Conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+Design+of+Inhibitors+That+Bind+to+Inactive+Kinase+Conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0likVNcQx-3V5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520Design%2520of%2520Inhibitors%2520That%2520Bind%2520to%2520Inactive%2520Kinase%2520Conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged approach for Kinase Inhibitor Focused Drug Discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0likVNcQx-3V5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemovska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span> <span> </span><span class="NLM_article-title">Axitinib Effectively Inhibits Bcr-Abl1(T315I) with a Distinct Binding Conformation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>519</i></span>,  <span class="NLM_fpage">102</span>, <span class="refDoi"> DOI: 10.1038/nature14119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnature14119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25686603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=2015&pages=102&author=T.+Pemovskaauthor=E.+Johnsonauthor=M.+Kontroauthor=G.+A.+Repaskyauthor=J.+Chenauthor=P.+Wellsauthor=C.+N.+Croninauthor=M.+McTigueauthor=O.+Kallioniemiauthor=K.+Porkkaauthor=B.+W.+Murrayauthor=K.+Wennerberg&title=Axitinib+Effectively+Inhibits+Bcr-Abl1%28T315I%29+with+a+Distinct+Binding+Conformation&doi=10.1038%2Fnature14119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation</span></div><div class="casAuthors">Pemovska, Tea; Johnson, Eric; Kontro, Mika; Repasky, Gretchen A.; Chen, Jeffrey; Wells, Peter; Cronin, Ciaran N.; McTigue, Michele; Kallioniemi, Olli; Porkka, Kimmo; Murray, Brion W.; Wennerberg, Krister</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">7541</span>),
    <span class="NLM_cas:pages">102-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukemia and 30-50% of cases of adult acute lymphoblastic leukemia.  Introduction of ABL1 kinase inhibitors (for example, imatinib) has markedly improved patient survival, but acquired drug resistance remains a challenge.  Point mutations in the ABL1 kinase domain weaken inhibitor binding and represent the most common clin. resistance mechanism.  The BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) confers resistance to all approved ABL1 inhibitors except ponatinib, which has toxicity limitations.  Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural anal. to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukemia.  Axitinib potently inhibited BCR-ABL1(T315I), at both biochem. and cellular levels, by binding to the active form of ABL1(T315I) in a mutation-selective binding mode.  These findings suggest that the T315I mutation shifts the conformational equil. of the kinase in favor of an active (DFG-in) A-loop conformation, which has more optimal binding interactions with axitinib.  Treatment of a T315I chronic myeloid leukemia patient with axitinib resulted in a rapid redn. of T315I-pos. cells from bone marrow.  Taken together, our findings demonstrate an unexpected opportunity to repurpose axitinib, an anti-angiogenic drug approved for renal cancer, as an inhibitor for ABL1 gatekeeper mutant drug-resistant leukemia patients.  This study shows that wild-type proteins do not always sample the conformations available to disease-relevant mutant proteins and that comprehensive drug testing of patient-derived cells can identify unpredictable, clin. significant drug-repositioning opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXgtLS5A1lLVg90H21EOLACvtfcHk0lggZJJvl-NdTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntbs%253D&md5=af8549ae0527bfcbda6d6e05b548f928</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14119%26sid%3Dliteratum%253Aachs%26aulast%3DPemovska%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKontro%26aufirst%3DM.%26aulast%3DRepasky%26aufirst%3DG.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DWennerberg%26aufirst%3DK.%26atitle%3DAxitinib%2520Effectively%2520Inhibits%2520Bcr-Abl1%2528T315I%2529%2520with%2520a%2520Distinct%2520Binding%2520Conformation%26jtitle%3DNature%26date%3D2015%26volume%3D519%26spage%3D102%26doi%3D10.1038%2Fnature14119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span> <span> </span><span class="NLM_article-title">Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">18281</span>– <span class="NLM_lpage">18289</span>, <span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+Conformations%2C+Interactions%2C+and+Properties+Associated+with+Drug+Efficiency+and+Clinical+Performance+among+VEGFR+TK+Inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0lggZJJvl-NdTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520Conformations%252C%2520Interactions%252C%2520and%2520Properties%2520Associated%2520with%2520Drug%2520Efficiency%2520and%2520Clinical%2520Performance%2520among%2520VEGFR%2520TK%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quenzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Kit Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.-A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.-M.+Zhangauthor=G.+D.+Demetri&title=Kit+Kinase+Mutants+Show+Unique+Mechanisms+of+Drug+Resistance+to+Imatinib+and+Sunitinib+in+Gastrointestinal+Stromal+Tumor+Patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lhyIZUNJrMBPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.-M.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKit%2520Kinase%2520Mutants%2520Show%2520Unique%2520Mechanisms%2520of%2520Drug%2520Resistance%2520to%2520Imatinib%2520and%2520Sunitinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kissova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespan, E.</span></span> <span> </span><span class="NLM_article-title">The Human Tyrosine Kinase Kit and Its Gatekeeper Mutant T670i, Show Different Kinetic Properties: Implications for Drug Design</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4562</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.07.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.bmc.2016.07.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=27527414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleqtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4555-4562&author=M.+Kissovaauthor=G.+Magaauthor=E.+Crespan&title=The+Human+Tyrosine+Kinase+Kit+and+Its+Gatekeeper+Mutant+T670i%2C+Show+Different+Kinetic+Properties%3A+Implications+for+Drug+Design&doi=10.1016%2Fj.bmc.2016.07.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design</span></div><div class="casAuthors">Kissova, Miroslava; Maga, Giovanni; Crespan, Emmanuele</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4555-4562</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrosine kinase Kit, a receptor for Stem Cell Factor, is involved, among others, in processes assocd. to cell survival, proliferation and migration.  Upon physiol. conditions, the activity of Kit is tightly regulated.  However, primary mutations that lead to its constitutive activation are the causal oncogenic driver of gastrointestinal stromal tumors (GISTs).  GISTs are known to be refractory to conventional therapies but the introduction of Imatinib, a selective inhibitor of tyrosine kinases Abl and Kit, significantly ameliorated the treatment options of GISTs patients.  However, the acquisition of secondary mutations renders Kit resistant towards all available drugs.  Mutation involving gatekeeper residues (such as V654a and T670I) influence both the structure and the catalytic activity of the enzyme.  Therefore, detailed knowledge of the enzymic properties of the mutant forms, in comparison with the wild type enzyme, is an important pre-requisite for the rational development of specific inhibitors.  In this paper the authors report a thorough kinetic anal. of the reaction catalyzed by the Kit kinase and its gatekeeper mutated form T670I.  The authors' results revealed the different mechanisms of action of these two enzymes and may open a new avenue for the future design of specific Kit inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxcDiQzpi2CLVg90H21EOLACvtfcHk0lhyIZUNJrMBPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleqtL3O&md5=5c056b79f7daf6d0bb3625c4f1768f55</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.07.059%26sid%3Dliteratum%253Aachs%26aulast%3DKissova%26aufirst%3DM.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DCrespan%26aufirst%3DE.%26atitle%3DThe%2520Human%2520Tyrosine%2520Kinase%2520Kit%2520and%2520Its%2520Gatekeeper%2520Mutant%2520T670i%252C%2520Show%2520Different%2520Kinetic%2520Properties%253A%2520Implications%2520for%2520Drug%2520Design%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4555%26epage%3D4562%26doi%3D10.1016%2Fj.bmc.2016.07.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112744. <a href="https://doi.org/10.1016/j.ejmech.2020.112744" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112744%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-methyl-5-%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thiazol-2-yl%252529-2-%2525284-methylpiperazin-1-yl%252529acetamide%252B%252528IHMT-TRK-284%252529%252Bas%252Ba%252Bnovel%252Borally%252Bavailable%252Btype%252BII%252BTRK%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bresistant%252Bmutants%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2020%26volume%3D207%26spage%3D112744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative c-KIT kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of the SAR exploration rationale. (A) Type I binding mode of compound <b>6</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). (B) Type II binding mode of compound <b>6</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (C) Surface illustration of the hydrophobic pocket created by the DFG-out flip of c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (D) Binding mode of compound <b>7</b> with c-KIT T670I (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (E) Surface illustration of the hydrophobic pocket created by the DFG-out flip of c-KIT T670I. (F) Surface illustration of the shallow hydrophobic groove adjacent to the hinge binding area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Z′-LYTE biochemical kinase assay characterization of compound <b>24</b> against c-KIT wt/T670I kinases. (B) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT wt in the colon cancer cell line COLO320DM. (C) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT wt in BaF3-tel-c-KIT cells. (D) Inhibitory activity of <b>24</b> to the phosphorylation of c-KIT T670I in BaF3-tel-c-KIT-T670I cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity profiling of compound <b>24</b>. (A) KINOMEscan profiling of <b>24</b> at a concentration of 1 μM against 468 kinases and mutants. (B, C) Z′-LYTE kinase assay of <b>24</b> against the kinase targets revealed from the KINOMEscan profiling in isogenic cell lines. The table shows the target kinases that had remaining activity of less than 1% control in the presence of 1 μM <b>24</b> and the IC<sub>50</sub> values of these kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic illustration of the binding mechanism of compound <b>24</b>. (A) Binding mode of <b>24</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (B) Binding mode of <b>24</b> with c-KIT T670I (generated from PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Characterization of the cellular effects of compound <b>24</b>. (A) Effects of <b>24</b> on the c-KIT-mediated signaling transduction pathways in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 1 h of inhibitor treatment. (B) Apoptosis induction effects of <b>24</b> in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 24 h of inhibitor treatment. (C) Cell cycle arresting effects of <b>24</b> in GIST-T1, GIST-T1-T670I, and GIST-5R cells after 24 h of inhibitor treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacodynamic effects of compound <b>24</b> on p-c-KIT, p-ErK, and p-AKT in a tumor from the GIST-5R xenograft mouse model with a single dosage of 100 mg/(kg day) p.o. administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor efficacy of compound <b>24</b> in the GIST-5R xenograft mouse model. Female nu/nu mice bearing established GIST-5R tumor were treated with <b>24</b> at 25, 50, and 100 mg/(kg day) or vehicle control. Daily oral administration was initiated when GIST-5R tumors had reached a size of 200 mm<sup>3</sup>. Each group contained four animals. Data = mean ± standard error of the mean. (A) Body weight change in mice for each daily dosing group of <b>24</b> and imatinib. Initial body weight was set as 100%. (B) Tumor size measurements of GIST-5R xenograft mice after <b>24</b> and imatinib treatment. (C) Representative photographs of tumors in each group after 25, 50, and 100 mg/(kg day) of <b>24</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group in a 28 day treatment period.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>7</b>, <b>11</b>, and <b>23</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl hydrogen malonate or 1,1-yclopropanedicarboxylic acid monomethyl ester, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate (HATU), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF), room temperature (rt), 2 h; (b) LiOH, MeOH, H<sub>2</sub>O, rt, 6 h; (c) R<sup>1</sup>NH<sub>2</sub>, HATU, DIPEA, DMF, rt, 2 h; (d) CF<sub>3</sub>COOH, dichloromethane (DCM), rt, 4 h.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Compounds <b>8</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-3-(trifluoromethyl)benzoic acid or 4-chloro-3-(trifluoromethyl)phenylacetic acid, HATU, DIPEA, DMF, rt, 2 h; (b) CF<sub>3</sub>COOH, DCM, rt, 4 h; (c) 4-chloro-3-(trifluoromethyl)phenyl isocyanate, DCM, rt, 8 h.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/medium/jm-2019-00176e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Compounds <b>12</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.9b00176/20190516/images/large/jm-2019-00176e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00176&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) arylboronic acid, Pd(Ph<sub>3</sub>P)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, reflux, 12 h; (b) dihydropyran, CH<sub>3</sub>SO<sub>3</sub>H, tetrahydrofuran (THF), reflux, 8 h; (c) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 20 h; (d) methyl hydrogen malonate, HATU, DIPEA, DMF, rt, 2 h; (e) LiOH, MeOH, H<sub>2</sub>O, rt, 6 h. (f) HATU, DIPEA, DMF, rt, 2 h; (g) CF<sub>3</sub>COOH, DCM, rt, 4 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Stromal Tumor</span>. <i>J. Gastrointest. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2078-6891.2012.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.3978%2Fj.issn.2078-6891.2012.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22943011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSnur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=189-208&author=X.+Zhaoauthor=C.+Yue&title=Gastrointestinal+Stromal+Tumor&doi=10.3978%2Fj.issn.2078-6891.2012.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Zhao, Xiaohui; Yue, Changjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gastrointestinal Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-208</span>CODEN:
                <span class="NLM_cas:coden">JGOOBI</span>;
        ISSN:<span class="NLM_cas:issn">2078-6891</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its unique biol. behavior, clinicopathol. features, mol. mechanisms, and treatment implications.  GIST is the most common mesenchymal neoplasm in the gastrointestinal tract and has emerged from a poorly understood and treatment resistant neoplasm to a well-defined tumor entity since the discovery of particular mol. abnormalities, KIT and PDGFRA gene mutations.  The understanding of GIST biol. at the mol. level promised the development of novel treatment modalities.  Diagnosis of GIST depends on the integrity of histol., immunohistochem. and mol. anal.  The risk assessment of the tumor behavior relies heavily on pathol. evaluation and significantly impacts clin. management.  In this review, historic review, epidemiol., pathogenesis and genetics, diagnosis, role of mol. anal., prognostic factor and treatment strategies have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZLlQkdrwIHbVg90H21EOLACvtfcHk0litYkiE3X2LEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSnur7P&md5=5c68011b08fc986273fd417c1bee554b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2078-6891.2012.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2078-6891.2012.031%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DC.%26atitle%3DGastrointestinal%2520Stromal%2520Tumor%26jtitle%3DJ.%2520Gastrointest.%2520Oncol.%26date%3D2012%26volume%3D3%26spage%3D189%26epage%3D208%26doi%3D10.3978%2Fj.issn.2078-6891.2012.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-Function Mutations of c-KIT in Human Gastrointestinal Stromal Tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-Function+Mutations+of+c-KIT+in+Human+Gastrointestinal+Stromal+Tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lj8SELaJWq3fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-Function%2520Mutations%2520of%2520c-KIT%2520in%2520Human%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindblom, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remotti, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldenborg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meis-Kindblom, J. M.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajal</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1002/jemt.1060180315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1002%2Fjemt.1060180315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=9588894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1998&pages=1259-1269&author=L.+G.+Kindblomauthor=H.+E.+Remottiauthor=F.+Aldenborgauthor=J.+M.+Meis-Kindblom&title=Gastrointestinal+Pacemaker+Cell+Tumor+%28GIPACT%29%3A+Gastrointestinal+Stromal+Tumors+Show+Phenotypic+Characteristics+of+the+Interstitial+Cells+of+Cajal&doi=10.1002%2Fjemt.1060180315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span></div><div class="casAuthors">Kindblom L G; Remotti H E; Aldenborg F; Meis-Kindblom J M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1259-69</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The interstitial cells of Cajal (ICC) form a complex cell network within the gastrointestinal tract wall where they function as a pacemaker system.  Expression of the kit proto-oncogene is essential for the development of this system.  The aim of our study was to examine the hypothesis that gastrointestinal stromal tumors differentiate toward cells with an ICC phenotype.  Ultrastructurally, 58 stromal tumors were characterized and found to share many features with ICC.  Seventy-eight stromal tumors were immunophenotyped, particularly with regard to the kit receptor.  All 78 tumors revealed strong, homogeneous immunoreactivity for the kit receptor as did ICC of adjacent and control gastrointestinal walls.  Focal hyperplasia and hypertrophy of kit receptor positive cells were also observed in the gastrointestinal wall adjacent to the tumors.  CD34 immunoreactivity observed in interstitial cells surrounding Auerbach's ganglia suggests that a subpopulation of ICC is CD34 positive and may explain why 56 of 78 stromal tumors were CD34 positive.  Thirty control tumors, including gastrointestinal leiomyomas and leiomyosarcomas, were all negative for the kit receptor.  We conclude that gastrointestinal stromal tumors show striking morphological and immunophenotypic similarities with ICC and that they may originate from stem cells that differentiate toward a pacemaker cell phenotype.  We propose that the noncommittal name "gastrointestinal stromal tumor" be replaced by gastrointestinal pacemaker cell tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo1_gLlQJ49LesJRIHUP1ofW6udTcc2eapWozMWxCfiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D&md5=fb5342253954593446205c2ea24b21e3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjemt.1060180315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjemt.1060180315%26sid%3Dliteratum%253Aachs%26aulast%3DKindblom%26aufirst%3DL.%2BG.%26aulast%3DRemotti%26aufirst%3DH.%2BE.%26aulast%3DAldenborg%26aufirst%3DF.%26aulast%3DMeis-Kindblom%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520Pacemaker%2520Cell%2520Tumor%2520%2528GIPACT%2529%253A%2520Gastrointestinal%2520Stromal%2520Tumors%2520Show%2520Phenotypic%2520Characteristics%2520of%2520the%2520Interstitial%2520Cells%2520of%2520Cajal%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D152%26spage%3D1259%26epage%3D1269%26doi%3D10.1002%2Fjemt.1060180315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennartsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönnstrand, L.</span></span> <span> </span><span class="NLM_article-title">Stem Cell Factor Receptor/C-Kit: From Basic Science to Clinical Implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1619</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+R%C3%B6nnstrand&title=Stem+Cell+Factor+Receptor%2FC-Kit%3A+From+Basic+Science+to+Clinical+Implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0libjZuQTbG0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DStem%2520Cell%2520Factor%2520Receptor%252FC-Kit%253A%2520From%2520Basic%2520Science%2520to%2520Clinical%2520Implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, T.</span></span> <span> </span><span class="NLM_article-title">Enrichment and Characterization of Murine Hematopoietic Stem Cells That Express C-Kit Molecule</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1007/BF01703451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1007%2FBF01703451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1991&pages=1706-1712&author=S.+Okadaauthor=H.+Nakauchiauthor=K.+Nagayoshiauthor=S.+Nishikawaauthor=S.+Nishikawaauthor=Y.+Miuraauthor=T.+Suda&title=Enrichment+and+Characterization+of+Murine+Hematopoietic+Stem+Cells+That+Express+C-Kit+Molecule&doi=10.1007%2FBF01703451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2FBF01703451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01703451%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DNakauchi%26aufirst%3DH.%26aulast%3DNagayoshi%26aufirst%3DK.%26aulast%3DNishikawa%26aufirst%3DS.%26aulast%3DNishikawa%26aufirst%3DS.%26aulast%3DMiura%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DT.%26atitle%3DEnrichment%2520and%2520Characterization%2520of%2520Murine%2520Hematopoietic%2520Stem%2520Cells%2520That%2520Express%2520C-Kit%2520Molecule%26jtitle%3DBlood%26date%3D1991%26volume%3D78%26spage%3D1706%26epage%3D1712%26doi%3D10.1007%2FBF01703451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oosterhuis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looijenga, L. H. J.</span></span> <span> </span><span class="NLM_article-title">Testicular Germ-Cell Tumors in a Broader Perspective</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/nrc1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnrc1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=15738984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=210-222&author=J.+W.+Oosterhuisauthor=L.+H.+J.+Looijenga&title=Testicular+Germ-Cell+Tumors+in+a+Broader+Perspective&doi=10.1038%2Fnrc1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular germ-cell tumors in a broader perspective</span></div><div class="casAuthors">Oosterhuis, J. Wolter; Looijenga, Leendert H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-222</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The germ-cell tumors are a fascinating group of neoplasms because of their unusual biol. and the spectacular therapeutic results that have been obtained in these tumors.  Traditionally, this group of neoplasms is presented in an organ-oriented approach.  However, recent clin. and exptl. data convincingly demonstrate that these neoplasms are one disease with sep. entities that can manifest themselves in different anatomical sites.  We propose five entities, in which the developmental potential is detd. by the maturation stage and imprinting status of the originating germ cell.  Recent progress begins to explain the apparent unpredictable development of germ-cell tumors and offers a basis for understanding their exquisite sensitivity to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNiWrq2TenmbVg90H21EOLACvtfcHk0ljfPpnhXWN9sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7Y%253D&md5=9d7ab492c16016d6ee364897a8cb08d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1568%26sid%3Dliteratum%253Aachs%26aulast%3DOosterhuis%26aufirst%3DJ.%2BW.%26aulast%3DLooijenga%26aufirst%3DL.%2BH.%2BJ.%26atitle%3DTesticular%2520Germ-Cell%2520Tumors%2520in%2520a%2520Broader%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D210%26epage%3D222%26doi%3D10.1038%2Fnrc1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriss, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span> <span> </span><span class="NLM_article-title">Signaling of C-Kit in Dendritic Cells Influences Adaptive Immunity</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1183</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05122.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1111%2Fj.1749-6632.2009.05122.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1183&publication_year=2010&pages=104-122&author=P.+Rayauthor=N.+Krishnamoorthyauthor=T.+B.+Orissauthor=A.+Ray&title=Signaling+of+C-Kit+in+Dendritic+Cells+Influences+Adaptive+Immunity&doi=10.1111%2Fj.1749-6632.2009.05122.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05122.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05122.x%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DP.%26aulast%3DKrishnamoorthy%26aufirst%3DN.%26aulast%3DOriss%26aufirst%3DT.%2BB.%26aulast%3DRay%26aufirst%3DA.%26atitle%3DSignaling%2520of%2520C-Kit%2520in%2520Dendritic%2520Cells%2520Influences%2520Adaptive%2520Immunity%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1183%26spage%3D104%26epage%3D122%26doi%3D10.1111%2Fj.1749-6632.2009.05122.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redegeld, F. A.</span></span> In  <i>Encyclopedia of Immunotoxicology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohr, H.-W.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2005</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1-5&author=F.+A.+Redegeldauthor=H.-W.+Vohr&title=Encyclopedia+of+Immunotoxicology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRedegeld%26aufirst%3DF.%2BA.%26btitle%3DEncyclopedia%2520of%2520Immunotoxicology%26aulast%3DVohr%26aufirst%3DH.-W.%26pub%3DSpringer%26date%3D2005%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussouar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazelin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauszig-Delamasure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldschneider, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlen, P.</span></span> <span> </span><span class="NLM_article-title">The Proto-Oncogene C-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.08.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.molcel.2018.08.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=413-425&author=H.+Wangauthor=A.+Boussouarauthor=L.+Mazelinauthor=S.+Tauszig-Delamasureauthor=Y.+Sunauthor=D.+Goldschneiderauthor=A.+Paradisiauthor=P.+Mehlen&title=The+Proto-Oncogene+C-Kit+Inhibits+Tumor+Growth+by+Behaving+as+a+Dependence+Receptor&doi=10.1016%2Fj.molcel.2018.08.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.08.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.08.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBoussouar%26aufirst%3DA.%26aulast%3DMazelin%26aufirst%3DL.%26aulast%3DTauszig-Delamasure%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGoldschneider%26aufirst%3DD.%26aulast%3DParadisi%26aufirst%3DA.%26aulast%3DMehlen%26aufirst%3DP.%26atitle%3DThe%2520Proto-Oncogene%2520C-Kit%2520Inhibits%2520Tumor%2520Growth%2520by%2520Behaving%2520as%2520a%2520Dependence%2520Receptor%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D72%26spage%3D413%26epage%3D425%26doi%3D10.1016%2Fj.molcel.2018.08.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbaspour
Babaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huri, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, F.</span></span> <span> </span><span class="NLM_article-title">Receptor Tyrosine Kinase (C-Kit) Inhibitors: A Potential Therapeutic Target in Cancer Cells</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2459</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour%0ABabaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Z.+Huriauthor=F.+Ahmadipour&title=Receptor+Tyrosine+Kinase+%28C-Kit%29+Inhibitors%3A+A+Potential+Therapeutic+Target+in+Cancer+Cells&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2eZZmfs9qMUxHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DHuri%26aufirst%3DH.%2BZ.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520Tyrosine%2520Kinase%2520%2528C-Kit%2529%2520Inhibitors%253A%2520A%2520Potential%2520Therapeutic%2520Target%2520in%2520Cancer%2520Cells%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarlomo-Rikala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tervahartiala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Effect of the Tyrosine Kinase Inhibitor Sti571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+Tyrosine+Kinase+Inhibitor+Sti571+in+a+Patient+with+a+Metastatic+Gastrointestinal+Stromal+Tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eZZmfs9qMUxHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Sti571%2520in%2520a%2520Patient%2520with%2520a%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogendoorn, P. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Glabbeke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertulli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I.</span></span> <span> </span><span class="NLM_article-title">Progression-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+W.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-Free+Survival+in+Gastrointestinal+Stromal+Tumours+with+High-Dose+Imatinib%3A+Randomised+Trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%2BW.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-Free%2520Survival%2520in%2520Gastrointestinal%2520Stromal%2520Tumours%2520with%2520High-Dose%2520Imatinib%253A%2520Randomised%2520Trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs through Secondary Gene Mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singer&title=Acquired+Resistance+to+Imatinib+in+Gastrointestinal+Stromal+Tumor+Occurs+through+Secondary+Gene+Mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lgxfTFPz7ktCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26atitle%3DAcquired%2520Resistance%2520to%2520Imatinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Occurs%2520through%2520Secondary%2520Gene%2520Mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumors and Activity of the Pkc412 Inhibitor against Imatinib-Resistant Mutants</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychter&title=Mechanisms+of+Resistance+to+Imatinib+Mesylate+in+Gastrointestinal+Stromal+Tumors+and+Activity+of+the+Pkc412+Inhibitor+against+Imatinib-Resistant+Mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Imatinib%2520Mesylate%2520in%2520Gastrointestinal%2520Stromal%2520Tumors%2520and%2520Activity%2520of%2520the%2520Pkc412%2520Inhibitor%2520against%2520Imatinib-Resistant%2520Mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandau, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4764</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+V.+von+Mehrenauthor=C.+D.+M.+Fletcherauthor=K.+Sandau&title=Molecular+Correlates+of+Imatinib+Resistance+in+Gastrointestinal+Stromal+Tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0ljnhi2O1uQQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%2BV.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSandau%26aufirst%3DK.%26atitle%3DMolecular%2520Correlates%2520of%2520Imatinib%2520Resistance%2520in%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span> <span> </span><span class="NLM_article-title">Kit Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+Dinittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacques&title=Kit+Kinase+Mutants+Show+Unique+Mechanisms+of+Drug+Resistance+to+Imatinib+and+Sunitinib+in+Gastrointestinal+Stromal+Tumor+Patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0ljnhi2O1uQQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDinitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26atitle%3DKit%2520Kinase%2520Mutants%2520Show%2520Unique%2520Mechanisms%2520of%2520Drug%2520Resistance%2520to%2520Imatinib%2520and%2520Sunitinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manola, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Regorafenib in Patients with Metastatic and/or Unresectable Gi Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2407</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.39.9394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1200%2FJCO.2011.39.9394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22614970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2401-2407&author=S.+Georgeauthor=Q.+Wangauthor=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=M.+Zhuauthor=J.+E.+Butrynskiauthor=J.+A.+Morganauthor=A.+J.+Wagnerauthor=E.+Choyauthor=W.+D.+Tapauthor=J.+T.+Yapauthor=A.+D.+Van+den+Abbeeleauthor=J.+B.+Manolaauthor=S.+M.+Solomonauthor=J.+A.+Fletcherauthor=M.+von+Mehrenauthor=G.+D.+Demetri&title=Efficacy+and+Safety+of+Regorafenib+in+Patients+with+Metastatic+and%2For+Unresectable+Gi+Stromal+Tumor+after+Failure+of+Imatinib+and+Sunitinib%3A+A+Multicenter+Phase+II+Trial&doi=10.1200%2FJCO.2011.39.9394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial</span></div><div class="casAuthors">George, Suzanne; Wang, Qian; Heinrich, Michael C.; Corless, Christopher L.; Zhu, Meijun; Butrynski, James E.; Morgan, Jeffrey A.; Wagner, Andrew J.; Choy, Edwin; Tap, William D.; Yap, Jeffrey T.; Van den Abbeele, Annick D.; Manola, Judith B.; Solomon, Sarah M.; Fletcher, Jonathan A.; von Mehren, Margaret; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2401-2407</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib.  Regorafenib is a structurally unique inhibitor of multiple cancer-assocd. kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclin. and early-phase trials.  Because KIT and PDGFR-α remain drivers of GIST after resistance to imatinib and sunitinib, we performed a multicenter single-stage phase II trial of regorafenib in patients with advanced GIST after failure of at least imatinib and sunitinib.  Patients and Methods: Patients received regorafenib orally, 160 mg daily, on days 1 to 21 of a 28-day cycle.  Disease assessment was performed every two cycles per RECIST 1.1.  Primary end point was clin. benefit rate (CBR), defined as objective responses (ie, complete or partial response [PR] as well as stable disease [SD] ≥ 16 wk).  Serial tumor biopsies were obtained from consenting patients whenever possible.  Results From Feb. to Dec. 2010, 34 patients were enrolled at four US centers.  As of July 28, 2011, 33 patients had received at least two cycles of regorafenib (range, two to 17 cycles).  CBR was 79% (95% CI, 61% to 91%).  Four patients achieved PR, and 22 exhibited SD ≥ 16 wk.  Median progression-free survival was 10.0 mo.  The most common grade 3 toxicities were hypertension and hand-foot-skin reaction.  Conclusion: Regorafenib has significant activity in patients with advanced GIST after failure of both imatinib and sunitinib.  A phase III trial of regorafenib vs. placebo is ongoing to define more fully the safety and efficacy of regorafenib in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RtWuSuSFcbVg90H21EOLACvtfcHk0liph6rMOaLfbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM&md5=54875f152708a1020a429f24cf398b30</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.39.9394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.39.9394%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DYap%26aufirst%3DJ.%2BT.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DManola%26aufirst%3DJ.%2BB.%26aulast%3DSolomon%26aufirst%3DS.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Regorafenib%2520in%2520Patients%2520with%2520Metastatic%2520and%252For%2520Unresectable%2520Gi%2520Stromal%2520Tumor%2520after%2520Failure%2520of%2520Imatinib%2520and%2520Sunitinib%253A%2520A%2520Multicenter%2520Phase%2520II%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2401%26epage%3D2407%26doi%3D10.1200%2FJCO.2011.39.9394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib Inhibits Polyclonal Drug-Resistant Kit Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (Gist) Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_fpage">5745</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=5745&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+Inhibits+Polyclonal+Drug-Resistant+Kit+Oncoproteins+and+Shows+Therapeutic+Potential+in+Heavily+Pretreated+Gastrointestinal+Stromal+Tumor+%28Gist%29+Patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0lgNXrr9gEcdVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520Inhibits%2520Polyclonal%2520Drug-Resistant%2520Kit%2520Oncoproteins%2520and%2520Shows%2520Therapeutic%2520Potential%2520in%2520Heavily%2520Pretreated%2520Gastrointestinal%2520Stromal%2520Tumor%2520%2528Gist%2529%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26spage%3D5745%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Repurposing Cabozantinib to Gists: Overcoming Multiple Imatinib-Resistant Ckit Mutations Including Gatekeeper and Activation Loop Mutants in Gists Preclinical Models</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.canlet.2019.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=30684595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1KntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2019&pages=105-114&author=T.+Luauthor=C.+Chenauthor=A.+Wangauthor=Z.+Jiangauthor=Z.+Qiauthor=Z.+Huauthor=C.+Huauthor=F.+Liuauthor=W.+Wangauthor=H.+Wuauthor=B.+Wangauthor=L.+Wangauthor=S.+Qiauthor=J.+Wuauthor=W.+Wangauthor=J.+Tangauthor=H.+Yanauthor=M.+Baiauthor=Q.+Liuauthor=J.+Liu&title=Repurposing+Cabozantinib+to+Gists%3A+Overcoming+Multiple+Imatinib-Resistant+Ckit+Mutations+Including+Gatekeeper+and+Activation+Loop+Mutants+in+Gists+Preclinical+Models&doi=10.1016%2Fj.canlet.2019.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models</span></div><div class="casAuthors">Lu, Tingting; Chen, Cheng; Wang, Aoli; Jiang, Zongru; Qi, Ziping; Hu, Zhenquan; Hu, Chen; Liu, Feiyang; Wang, Wenliang; Wu, Hong; Wang, Beilei; Wang, Li; Qi, Shuang; Wu, Jiaxin; Wang, Wenchao; Tang, Jun; Yan, Hezhong; Bai, Mingfeng; Liu, Qingsong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105-114</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Despite of the great success of imatinib as the first-line treatment for GISTs, the majority of patients will develop drug-acquired resistance due to secondary mutations in the cKIT kinase.  Sunitinib and regorafenib have been approved as the second and third line therapies to overcome some of these drug-resistance mutations; however, their limited clin. response, toxicity and resistance of the activation loop mutants still makes new therapies bearing different cKIT mutants activity spectrum profile highly demanded.  Through a drug repositioning approach, we found that cabozantinib exhibited higher potency than imatinib against primary gain-of-function mutations of cKIT.  Moreover, cabozantinib was able to overcome cKIT gatekeeper T670I mutation and the activation loop mutations that are resistant to imatinib or sunitinib.  Cabozantinib demonstrated good efficacy in vitro and in vivo in the cKIT mutant-driven preclin. models of GISTs while displaying a long-lasting effect after treatment withdrawal.  Furthermore, it also exhibited dose-dependent anti-proliferative efficacy in the GIST patient derived primary cells.  Considering clin. safety and PK profile of cabozantinib, this report provides the basis for the future clin. applications of cabozantinib as an alternative anti-GISTs therapy in precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCgeJxg7EnwrVg90H21EOLACvtfcHk0lgNXrr9gEcdVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1KntL8%253D&md5=60675118394473184bf297320107e6a8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRepurposing%2520Cabozantinib%2520to%2520Gists%253A%2520Overcoming%2520Multiple%2520Imatinib-Resistant%2520Ckit%2520Mutations%2520Including%2520Gatekeeper%2520and%2520Activation%2520Loop%2520Mutants%2520in%2520Gists%2520Preclinical%2520Models%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D447%26spage%3D105%26epage%3D114%26doi%3D10.1016%2Fj.canlet.2019.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunnarsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfanzelter, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, S. M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Safety and Efficacy of Axitinib in the Treatment of Advanced Renal Cell Carcinoma</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S74202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.2147%2FCMAR.S74202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25709499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVShur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=65-73&author=O.+Gunnarssonauthor=N.+R.+Pfanzelterauthor=R.+B.+Cohenauthor=S.+M.+Keefe&title=Evaluating+the+Safety+and+Efficacy+of+Axitinib+in+the+Treatment+of+Advanced+Renal+Cell+Carcinoma&doi=10.2147%2FCMAR.S74202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma</span></div><div class="casAuthors">Gunnarsson, Orvar; Pfanzelter, Nicklas R.; Cohen, Roger B.; Keefe, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit.  Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in Phase II trials.  The trial of comparative effectivess of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS) was an international randomized Phase III study designed for registration purposes, compared axitinib to sunitinib.  This trial randomized 723 patients with metastatic kidney cancer to axitinib or sunitinib in the second-line setting and demonstrated a median progression-free survival of 6.7 mo for axitinib vs. 4.7 mo for sorafenib (P<0.0001).  Clin. benefit was detected regardless of prior therapy, but no overall survival benefit has been obsd.  Axitinib is well tolerated without a significant effect on quality of life.  The most common grade 3 toxicities are hypertension (16%), diarrhea (11%), and fatigue (11%), with other notable side effects being anorexia, nausea, hand-foot syndrome, and rash.  Patients who developed diastolic blood pressure >90 mmHg were noted to have significantly longer median overall survival and overall response rates when compared to normotensive patients.  Therefore, the manufacturer recommends escalating the twice-daily dose to 7 mg and 10 mg, as tolerated, if there is no significant increase in blood pressure on treatment.  Currently, axitinib is approved for use in the second-line setting for patients with metastatic renal cell carcinoma.  Research is ongoing in other disease settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVP3EHxMBIWLVg90H21EOLACvtfcHk0li27ZG5ZFjJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVShur%252FM&md5=4d9aeb0b16a4eed78dfab565d41a6edd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S74202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S74202%26sid%3Dliteratum%253Aachs%26aulast%3DGunnarsson%26aufirst%3DO.%26aulast%3DPfanzelter%26aufirst%3DN.%2BR.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DKeefe%26aufirst%3DS.%2BM.%26atitle%3DEvaluating%2520the%2520Safety%2520and%2520Efficacy%2520of%2520Axitinib%2520in%2520the%2520Treatment%2520of%2520Advanced%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2015%26volume%3D7%26spage%3D65%26epage%3D73%26doi%3D10.2147%2FCMAR.S74202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0li27ZG5ZFjJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790m</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+against+EGFR+T790m&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lice0s-H5XqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520against%2520EGFR%2520T790m%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Inhibitors That Bind to Inactive Kinase Conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+Design+of+Inhibitors+That+Bind+to+Inactive+Kinase+Conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lice0s-H5XqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520Design%2520of%2520Inhibitors%2520That%2520Bind%2520to%2520Inactive%2520Kinase%2520Conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged approach for Kinase Inhibitor Focused Drug Discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lik-5UrkH2ktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemovska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span> <span> </span><span class="NLM_article-title">Axitinib Effectively Inhibits Bcr-Abl1(T315I) with a Distinct Binding Conformation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>519</i></span>,  <span class="NLM_fpage">102</span>, <span class="refDoi"> DOI: 10.1038/nature14119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1038%2Fnature14119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=25686603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=2015&pages=102&author=T.+Pemovskaauthor=E.+Johnsonauthor=M.+Kontroauthor=G.+A.+Repaskyauthor=J.+Chenauthor=P.+Wellsauthor=C.+N.+Croninauthor=M.+McTigueauthor=O.+Kallioniemiauthor=K.+Porkkaauthor=B.+W.+Murrayauthor=K.+Wennerberg&title=Axitinib+Effectively+Inhibits+Bcr-Abl1%28T315I%29+with+a+Distinct+Binding+Conformation&doi=10.1038%2Fnature14119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation</span></div><div class="casAuthors">Pemovska, Tea; Johnson, Eric; Kontro, Mika; Repasky, Gretchen A.; Chen, Jeffrey; Wells, Peter; Cronin, Ciaran N.; McTigue, Michele; Kallioniemi, Olli; Porkka, Kimmo; Murray, Brion W.; Wennerberg, Krister</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">7541</span>),
    <span class="NLM_cas:pages">102-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukemia and 30-50% of cases of adult acute lymphoblastic leukemia.  Introduction of ABL1 kinase inhibitors (for example, imatinib) has markedly improved patient survival, but acquired drug resistance remains a challenge.  Point mutations in the ABL1 kinase domain weaken inhibitor binding and represent the most common clin. resistance mechanism.  The BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) confers resistance to all approved ABL1 inhibitors except ponatinib, which has toxicity limitations.  Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural anal. to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukemia.  Axitinib potently inhibited BCR-ABL1(T315I), at both biochem. and cellular levels, by binding to the active form of ABL1(T315I) in a mutation-selective binding mode.  These findings suggest that the T315I mutation shifts the conformational equil. of the kinase in favor of an active (DFG-in) A-loop conformation, which has more optimal binding interactions with axitinib.  Treatment of a T315I chronic myeloid leukemia patient with axitinib resulted in a rapid redn. of T315I-pos. cells from bone marrow.  Taken together, our findings demonstrate an unexpected opportunity to repurpose axitinib, an anti-angiogenic drug approved for renal cancer, as an inhibitor for ABL1 gatekeeper mutant drug-resistant leukemia patients.  This study shows that wild-type proteins do not always sample the conformations available to disease-relevant mutant proteins and that comprehensive drug testing of patient-derived cells can identify unpredictable, clin. significant drug-repositioning opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXgtLS5A1lLVg90H21EOLACvtfcHk0lik-5UrkH2ktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntbs%253D&md5=af8549ae0527bfcbda6d6e05b548f928</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14119%26sid%3Dliteratum%253Aachs%26aulast%3DPemovska%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKontro%26aufirst%3DM.%26aulast%3DRepasky%26aufirst%3DG.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DWennerberg%26aufirst%3DK.%26atitle%3DAxitinib%2520Effectively%2520Inhibits%2520Bcr-Abl1%2528T315I%2529%2520with%2520a%2520Distinct%2520Binding%2520Conformation%26jtitle%3DNature%26date%3D2015%26volume%3D519%26spage%3D102%26doi%3D10.1038%2Fnature14119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span> <span> </span><span class="NLM_article-title">Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">18281</span>– <span class="NLM_lpage">18289</span>, <span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+Conformations%2C+Interactions%2C+and+Properties+Associated+with+Drug+Efficiency+and+Clinical+Performance+among+VEGFR+TK+Inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0liSbgUL4WvwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520Conformations%252C%2520Interactions%252C%2520and%2520Properties%2520Associated%2520with%2520Drug%2520Efficiency%2520and%2520Clinical%2520Performance%2520among%2520VEGFR%2520TK%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quenzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Kit Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.-A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.-M.+Zhangauthor=G.+D.+Demetri&title=Kit+Kinase+Mutants+Show+Unique+Mechanisms+of+Drug+Resistance+to+Imatinib+and+Sunitinib+in+Gastrointestinal+Stromal+Tumor+Patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0liSbgUL4WvwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.-M.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKit%2520Kinase%2520Mutants%2520Show%2520Unique%2520Mechanisms%2520of%2520Drug%2520Resistance%2520to%2520Imatinib%2520and%2520Sunitinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kissova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespan, E.</span></span> <span> </span><span class="NLM_article-title">The Human Tyrosine Kinase Kit and Its Gatekeeper Mutant T670i, Show Different Kinetic Properties: Implications for Drug Design</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4562</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.07.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=10.1016%2Fj.bmc.2016.07.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=27527414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleqtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4555-4562&author=M.+Kissovaauthor=G.+Magaauthor=E.+Crespan&title=The+Human+Tyrosine+Kinase+Kit+and+Its+Gatekeeper+Mutant+T670i%2C+Show+Different+Kinetic+Properties%3A+Implications+for+Drug+Design&doi=10.1016%2Fj.bmc.2016.07.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design</span></div><div class="casAuthors">Kissova, Miroslava; Maga, Giovanni; Crespan, Emmanuele</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4555-4562</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrosine kinase Kit, a receptor for Stem Cell Factor, is involved, among others, in processes assocd. to cell survival, proliferation and migration.  Upon physiol. conditions, the activity of Kit is tightly regulated.  However, primary mutations that lead to its constitutive activation are the causal oncogenic driver of gastrointestinal stromal tumors (GISTs).  GISTs are known to be refractory to conventional therapies but the introduction of Imatinib, a selective inhibitor of tyrosine kinases Abl and Kit, significantly ameliorated the treatment options of GISTs patients.  However, the acquisition of secondary mutations renders Kit resistant towards all available drugs.  Mutation involving gatekeeper residues (such as V654a and T670I) influence both the structure and the catalytic activity of the enzyme.  Therefore, detailed knowledge of the enzymic properties of the mutant forms, in comparison with the wild type enzyme, is an important pre-requisite for the rational development of specific inhibitors.  In this paper the authors report a thorough kinetic anal. of the reaction catalyzed by the Kit kinase and its gatekeeper mutated form T670I.  The authors' results revealed the different mechanisms of action of these two enzymes and may open a new avenue for the future design of specific Kit inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxcDiQzpi2CLVg90H21EOLACvtfcHk0lj21jNhZFzWHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleqtL3O&md5=5c056b79f7daf6d0bb3625c4f1768f55</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.07.059%26sid%3Dliteratum%253Aachs%26aulast%3DKissova%26aufirst%3DM.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DCrespan%26aufirst%3DE.%26atitle%3DThe%2520Human%2520Tyrosine%2520Kinase%2520Kit%2520and%2520Its%2520Gatekeeper%2520Mutant%2520T670i%252C%2520Show%2520Different%2520Kinetic%2520Properties%253A%2520Implications%2520for%2520Drug%2520Design%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4555%26epage%3D4562%26doi%3D10.1016%2Fj.bmc.2016.07.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TWP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TWP','PDB','4TWP'); return false;">PDB: 4TWP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8','PDB','4AG8'); return false;">PDB: 4AG8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i89"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00176">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17801"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00176">10.1021/acs.jmedchem.9b00176</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Listing the DiscoverX’s KINOMEscan selectivity profiling data of <b>24</b> (Supplementary Table 1); listing the pharmacodynamic evaluation of <b>24</b> in the GIST-5R xenograft mouse model (Supplementary Figure 1) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docking poses for <b>6</b>, <b>7</b>, and <b>24</b> with c-KIT T670I and docking pose for <b>24</b> with c-KIT wt (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_003.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_001.pdf">jm9b00176_si_001.pdf (781.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_002.csv">jm9b00176_si_002.csv (4.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00176/suppl_file/jm9b00176_si_003.zip">jm9b00176_si_003.zip (281.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00176&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00176%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-10%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00176" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0db386aa51964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
